This document provides methods and materials related to induced pluripotent stem cells. For example, induced pluripotent stem cells, compositions containing induced pluripotent stem cells, methods for obtaining induced pluripotent stem cells, and methods for using induced pluripotent stem cells are provided. In addition, methods and materials for using induced pluripotent stem cells to repair tissue (e.g., cardiovascular tissue) in vivo as well as methods and materials for using induced pluripotent stem cells to assess their therapeutic potential in appropriate animal models are provided.
INDUCED PLURIPOTENT STEM CELLS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority to U.S. Provisional Application Serial No. To Be Assigned, filed August 5, 2009; U.S. Provisional Application Serial No. 61/271,341, filed July 20, 2009; and U.S. Provisional Application Serial No. 61/087,492, filed August 8, 2008. The disclosures of the prior applications are considered part of (and are incorporated by reference in) the disclosure of this application.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

This invention was made with government support under R01HL083439 and T32HL007111 awarded by National Institutes of Health. The government has certain rights in the invention.

BACKGROUND

1. Technical Field

This document relates to methods and materials involved in making and using induced pluripotent stem cells.

2. Background Information

Stem cells are characterized by the ability of self-renewal and differentiation into a diverse range of cell types. The two broad types of mammalian stem cells are embryonic stem (ES) cells and adult stem cells. Adult stem cells or progenitor cells replenish specialized cells to repair or maintain regenerative organs. Most adult stem cells are lineage-restricted and generally referred to by their tissue origin, such as adipose-derived stem cells. ES cell lines are derived from the epiblast tissue of the inner cell mass of a blastocyst or early morula stage embryos. ES cells are pluripotent and give rise to derivatives of the three germinal layers, i.e., the ectoderm, endoderm and mesoderm.
SUMMARY

This document provides methods and materials related to induced pluripotent stem cells. For example, this document provides induced pluripotent stem cells, compositions containing induced pluripotent stem cells, methods for obtaining induced pluripotent stem cells, and methods for using induced pluripotent stem cells (e.g., methods for using induced pluripotent stem cells to repair cardiovascular tissue). In some cases, the induced pluripotent stem cells and compositions containing induced pluripotent stem cells can be used to assess their therapeutic potential in appropriate animal models. For example, induced pluripotent stem cells of mouse origin that were created using human factors can be assessed in mice for therapeutic potential and for safety (e.g., the ability to not form cancerous cells).

In general, one aspect of this document features an induced pluripotent stem cell comprising nucleic acid encoding one or more polypeptides selected from the group consisting of a human Oct3/4 POU family polypeptide (e.g., a human Oct3/4 polypeptide), a human Sox family polypeptide, a human KIf family polypeptide, a human Myc family polypeptide, a human Nanog polypeptide, and a human Lin28 polypeptide, wherein the origin of the induced pluripotent stem cell is a non-human species. The non-human species can be selected from the group consisting of mouse, rat, hamster, guinea pig, rabbit, cat, dog, pig, sheep, goat, cow, horse, and monkey species. The induced pluripotent stem cell can be induced from a somatic cell. The somatic cell can be selected from the group consisting of skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells. The human Sox family polypeptide can be a Sox2 polypeptide. The human KIf family polypeptide can be a KIf4 polypeptide. The human Myc family polypeptide can be a c-Myc polypeptide. The induced pluripotent stem cell can comprise nucleic acid encoding the human Oct3/4 POU family polypeptide (e.g., a human Oct3/4 polypeptide), the human Sox2 polypeptide, the human KIf4 polypeptide, and the human c-Myc polypeptide.

In another aspect, this document features an induced pluripotent stem cell comprising nucleic acid encoding one or more polypeptides selected from the group consisting of a non-human Oct3/4 POU family polypeptide (e.g., a non-human Oct3/4 polypeptide), a non-human Sox family polypeptide, a non-human KIf family polypeptide, a non-human Myc family polypeptide, a non-human Nanog polypeptide, and a non-human Lin28 polypeptide, wherein the origin of the induced pluripotent stem cell is human. The one or more polypeptides can be of mouse, rat, hamster, guinea pig, rabbit, cat, dog, pig, sheep, goat, cow, horse or monkey origin.
The induced pluripotent stem cell can be induced from a human somatic cell. The human somatic cell can be selected from the group consisting skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells. The non-human Sox family polypeptide can be a Sox2 polypeptide. The non-human Klf family polypeptide can be a Klf4 polypeptide. The non-human Myc family polypeptide can be a c-Myc polypeptide. The induced pluripotent stem cell can comprise nucleic acid encoding the non-human Oct3/4 POU family polypeptide (e.g., a non-human Oct3/4 polypeptide), a non-human Sox2 polypeptide, a non-human Klf4 polypeptide, and a non-human c-Myc polypeptide.

In another aspect, this document features an induced pluripotent stem cell, wherein the induced pluripotent stem cell was obtained using nucleic acid encoding one or more polypeptides selected from the group consisting of a human Oct3/4 POU family polypeptide (e.g., a human Oct3/4 polypeptide), a human Sox family polypeptide, a human Klf family polypeptide, a human Myc family polypeptide, a human Nanog polypeptide, and a human Lin28 polypeptide, wherein the origin of the induced pluripotent stem cell is a non-human species. The non-human species can be selected from the group consisting of mouse, rat, hamster, guinea pig, rabbit, cat, dog, pig, sheep, goat, cow, horse, and monkey species. The induced pluripotent stem cell can be induced from a somatic cell. The somatic cell can be selected from the group consisting of skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells. The human Sox family polypeptide can be a Sox2 polypeptide. The human Klf family polypeptide can be a Klf4 polypeptide. The human Myc family polypeptide can be a c-Myc polypeptide. The induced pluripotent stem cell can comprise nucleic acid encoding the human Oct3/4 POU family polypeptide (e.g., a human Oct3/4 polypeptide), a human Sox2 polypeptide, a human Klf4 polypeptide, and a human c-Myc polypeptide.

In another aspect, this document features an induced pluripotent stem cell, wherein the induced pluripotent stem cell was obtained using nucleic acid encoding one or more polypeptides selected from the group consisting of a non-human Oct3/4 POU family polypeptide (e.g., a non-human Oct3/4 polypeptide), a non-human Sox family polypeptide, a non-human Klf family polypeptide, a non-human Myc family polypeptide, a non-human Nanog polypeptide, and a non-human Lin28 polypeptide, wherein the origin of the induced pluripotent stem cell is human. The one or more polypeptides can be of mouse, rat, hamster, guinea pig, rabbit, cat, dog, pig, sheep, goat, cow, horse or monkey origin. The induced pluripotent stem cell can be induced from a
human somatic cell. The human somatic cell can be selected from the group consisting of skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells. The non-human Sox family polypeptide can be a Sox2 polypeptide. The non-human Klf family polypeptide can be a Klf4 polypeptide. The non-human Myc family polypeptide can be a c-Myc polypeptide. The induced pluripotent stem cell can comprise nucleic acid encoding the non-human Oct3/4 POU family polypeptide (e.g., a non-human Oct3/4 polypeptide), a non-human Sox2 polypeptide, a non-human Klf4 polypeptide, and a non-human c-Myc polypeptide.

In another aspect, this document features an induced pluripotent stem cell, wherein the induced pluripotent stem cell was obtained using a non-integrating vector comprising nucleic acid encoding one or more polypeptides selected from the group consisting of an Oct3/4 POU family polypeptide (e.g., a human Oct3/4 polypeptide), a Sox family polypeptide, a Klf family polypeptide, a Myc family polypeptide, a Nanog polypeptide, and a Lin28 polypeptide, wherein the induced pluripotent stem cell lacks the nucleic acid. The vector can be a viral vector. The vector can be a non-viral vector.

In another aspect, this document features a method for obtaining a population of induced pluripotent stem cells, wherein the method comprises (a) providing cells with nucleic acid encoding Oct3/4, Sox2, Klf4, and c-Myc polypeptides, and (b) culturing the cells with medium lacking serum under conditions to obtain the population of induced pluripotent stem cells. The medium can lack feeder cells. The medium can lack non-human feeder cells.

In another aspect, this document features a method for repairing diseased heart tissue in a mammal. The method comprises, or consists essentially of, administering induced pluripotent stem cells to the mammal under conditions wherein the diseased heart tissue is repaired, wherein the induced pluripotent stem cells were obtained using one or more polypeptides or nucleic acid encoding the one or more polypeptides selected from the group consisting of a Oct3/4 POU family polypeptide (e.g., a Oct3/4 polypeptide), a Sox family polypeptide, a Klf family polypeptide, a Myc family polypeptide, a Nanog polypeptide, and a Lin28 polypeptide. The administering step can comprise an intramyocardial administration. Progeny of the induced pluripotent stem cells can become engrafted into heart tissue of the mammal. Progeny of the induced pluripotent stem cells can become engrafted into heart tissue of the mammal without disrupting cytoarchitecture. The method can restore contractile performance, ventricular wall thickness, or electrical stability. The method can restore contractile performance, ventricular
wall thickness, and electrical stability. The administering step can result in the regeneration of cardiac, smooth muscle, or endothelial tissue. The administering step can result in the regeneration of cardiac, smooth muscle, and endothelial tissue. In some cases, the induced pluripotent stem cells were induced from somatic cells. The somatic cells can be selected from the group consisting of skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells. The Sox family polypeptide can be a human or non-human Sox2 polypeptide. The Klf family polypeptide can be a human or non-human Klf4 polypeptide. The Myc family polypeptide can be a human or non-human c-Myc polypeptide. The induced pluripotent stem cells can comprise nucleic acid encoding a human Oct3/4 POU family polypeptide (e.g., a human Oct3/4 polypeptide), a human Sox2 polypeptide, a human Klf4 polypeptide, and a human c-Myc polypeptide. The Oct3/4 POU family polypeptide can be a human Oct3/4 polypeptide. The Nanog polypeptide can be a human Nanog polypeptide. The Lin28 polypeptide can be a human Lin28 polypeptide. In some cases, the induced pluripotent stem cells were induced from human somatic cells.

In another aspect, this document features a method for regenerating cardiovascular tissue in a mammal. The method comprises, or consists essentially of, administering induced pluripotent stem cells to the mammal under conditions wherein progeny of the induced pluripotent stem cells become engrafted with cardiovascular tissue of the mammal, wherein the induced pluripotent stem cells were obtained using one or more polypeptides or nucleic acid encoding the one or more polypeptides selected from the group consisting of an Oct3/4 POU family polypeptide (e.g., a human Oct3/4 polypeptide), a Sox family polypeptide, a Klf family polypeptide, a Myc family polypeptide, a Nanog polypeptide, and a Lin28 polypeptide. The administering step can comprise an intramyocardial administration. The progeny can become engrafted into heart tissue of the mammal. The progeny can become engrafted into heart tissue of the mammal without disrupting cytoarchitecture. The method can restore contractile performance, ventricular wall thickness, or electrical stability. The method can restore contractile performance, ventricular wall thickness, and electrical stability. The administering step can result in the regeneration of cardiac, smooth muscle, or endothelial tissue. The administering step can result in the regeneration of cardiac, smooth muscle, and endothelial tissue. In some cases, the induced pluripotent stem cells were induced from somatic cells. The somatic cells can be selected from the group consisting of skin, lung, heart, stomach, brain, liver,
blood, kidney, and muscle cells. The Sox family polypeptide can be a human or non-human Sox2 polypeptide. The KIf family polypeptide can be a human or non-human Klf4 polypeptide. The Myc family polypeptide can be a human or non-human c-Myc polypeptide. The induced pluripotent stem cells can comprise nucleic acid encoding a human Oct3/4 POU family polypeptide (e.g., a human Oct3/4 polypeptide), a human Sox2 polypeptide, a human Klf4 polypeptide, and a human c-Myc polypeptide. The Oct3/4 POU family polypeptide can be a human Oct3/4 polypeptide. The Nanog polypeptide can be a human Nanog polypeptide. The Lin28 polypeptide can be a human Lin28 polypeptide. In some cases, the induced pluripotent stem cells were induced from human somatic cells.

In another aspect, this document features a population of cardiomyoctes derived from induced pluripotent stem cells. The induced pluripotent stem cells were obtained using a human Oct3/4 POU family polypeptide (e.g., a human Oct3/4 polypeptide), a human Sox family polypeptide, and a human KIf family polypeptide or nucleic acid encoding the human Oct3/4 polypeptide, the human Sox family polypeptide, and the human KIf family polypeptide, wherein the origin of the induced pluripotent stem cell is human, and wherein the induced pluripotent stem cells were not contacted with an exogenous human c-Myc polypeptide. The induced pluripotent stem cell was induced from a human somatic cell. The human somatic cell can be selected from the group consisting skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells. The human Sox family polypeptide can be a Sox2 polypeptide. The human KIf family polypeptide can be a Klf4 polypeptide. The induced pluripotent stem cell can comprise nucleic acid encoding the human Oct3/4 polypeptide, a human Sox2 polypeptide, and a human Klf4 polypeptide.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF THE DRAWINGS

Figure 1 is a photograph of a Western blot used to assess the generation of lentiviral vectors expressing stem cell-related genes. Oct3/4, Sox2, Klf4 and c-Myc expression was verified in the vector-infected 293T cells by immunoblotting with specific monoclonal antibodies.

Figure 2 contains photographs of cells demonstrating that lentiviral vector-mediated delivery of Oct3/4, Sox2, Klf4, and c-Myc results in ES-like colony formation. (A) Mouse SNL feeder cells. (B) Primary human cardiac fibroblasts (HCF). (C) Mitotically-inactivated SNL feeder cells after three weeks in culture. (D)(E) HCF-derived ES/iPS-like colonies. Colonies were flat and tightly packed. (F) Image of HCF-derived ES/iPS-like cells with high magnification. Each cell exhibited morphology similar to those of human ES and iPS cells, characterized by large nuclei and scant cytoplasm. (G) Human lung fibroblast MRC-5 cells. (H) Image of large MRC-5-derived ES/iPS-like colony. (I) Human foreskin fibroblasts BJ cells. (J) BJ-derived ES/iPS-like colony. (K) Image of a BJ-derived ES/iPS-like clone after expansion for three months in culture. (L) The BJ-derived ES/iPS-like cells with high magnification.

Figure 3 is a table providing the number of ES/iPS-like colonies formed after infection with HIV vectors expressing iPS-related factors.

Figure 4 contains photographs of putative human iPS colonies expressing alkaline phosphatase. All iPS-like colonies tested expressed alkaline phosphatase.

Figure 5 contains photographs demonstrating an induced pluripotent phenotype from human fibroblasts. All iPS-like colonies tested expressed human ES/iPS markers, SSEA4, TRA-1-60, and TRA-1-81, but not SSEA1.

Figure 6 contains photographs of mouse cells demonstrating that mouse iPS-like colonies can be derived from mouse embryonic fibroblasts. (A) Mouse embryonic fibroblast cells. (B) Tightly packed ES/iPS-like colonies were observed 10 days after vector transduction. (C) Single clone-derived iPS-like colonies. (D) Mouse ES cell colonies.

Figure 7 contains images of induced pluripotent phenotype from mouse embryonic
fibroblasts. MEF cells express Ki67 without SSEA-I in the uninduced state. iPS cells derived from MEF’s increase Ki67 expression and develop strong SSEA-I expression.

Figure 8 is a graph plotting the expression of the indicated markers. EB in vitro differentiation revealed significant expression of markers of gastrulation, indicating formation of all three germ layers.

Figure 9 contains photographs of iPS cell engraftment into host morula. (A) iPS cells were genetically labeled with GFP-expression tag and prepared as cell dumps. (B) Diploid aggregation with unlabeled morula stage embryo revealed incorporation into inner cell mass of the developing blastocytes.

Figure 10 contains photographs demonstrating the in vivo differentiation of mouse iPS cells into teratoma-like masses. (A) Four weeks after subcutaneous injection of a mouse iPS clone in a nude mouse resulted in formation of teratoma-like masses. (B)(C)(D) HE staining revealed typical multi-lineage tissue differentiation.

Figure 11 contains photographs demonstrating the generation of putative iPS cells from rat, hamster, and rhesus monkey cells. (A) Rat iPS-like colonies. (B) Rat iPS-like colonies (higher magnification). (C) Chinese hamster-derived iPS-like colonies (higher magnification). (D) Parental Rhesus kidney-derived cell line. (E) and (F) Rhesus monkey iPS-like colonies. (G) Image of rhesus iPS-like cells with high magnification. Each cell exhibited morphology similar to those of human iPS cells, characterized by large nuclei and scant cytoplasm.

Figure 12 contains photographs of non-invasive live imaging of HIV vector-infected cells. Luciferase-expressing HIV vector-infected cells were monitored by Xenogen IVIS imaging machine. Left panel: 1 week after subcutaneous administration of Luciferase-expressing HIV vector. Right panel: 1 week after intravenous administration of the same vector.

Figure 13 contains photographs demonstrating the feeder-free generation of human iPS-like cells. iPS-like colonies generated without mouse SNL feeder cells were expanded on mitotically inactivated MRC-5 cells. All the clones tested expressed alkaline phosphatase and human ES/iPS markers, SSEA4, TRA-1-60, and TRA-1-81.

Figure 14. Integration-free transgene expression. HIV-based vectors with mutations in the viral Integrase do not integrate into host genome and express transgene products without integration. AAV-based vectors also express transgene products without integrating into host genome.
Figure 15. Expression of GFP in human cells transduced with an AAV serotype 9 vector. 2 x 10^5 cells were infected with 1 µL of a concentrated GFP-expressing AAV9 vector. GFP-positive cells were analyzed by FACS at 2 days after infection.

Figure 16 is a schematic of uses of iPS cells provided herein.

Figure 17. Induced pluripotent stem cells (iPS) demonstrate pluripotent features. A, Flat fibroblasts reprogrammed with human sternness factors metamorphosed into rounded clusters shown by field-emission scanning electron microscopy. Bar = 50 µm. B, In transmission electron microscopy, derived iPS demonstrated nuclear/cytoplasmic composition similar to embryonic stem cells (ES). C, Counterstained by nuclear DAPI, iPS expressed the pluripotent marker SSEA-1, absent from fibroblasts (0 h; left). Bar = 5 µm. D, Fibroblasts or iPS clumps were placed along with two 8-cell host embryos for diploid aggregation (1 hour; top). Bar = 30 µm. Within 24 hours, iPS spontaneously integrated to form an early stage chimeric blastocyst (24 hours; bottom right), in contrast to fibroblasts that were excluded (24 hours; bottom left).

Figure 18. iPS recapitulate in utero cardiogenic propensity. A, LacZ-labeled iPS clones, detected by β-galactosidase (β-gal) staining, were maintained as undifferentiated colonies at day 0 before aggregation into embryoid bodies (EB). B, Gene expression profiles at day 0 (d0) compared to day 12 (d12) of differentiation demonstrated induction of cardiac transcription factors, Mef2c (p=0.049; n=3), Gata4 (p=0.049; n=3), and Myocardin (p=0.049; n=3). C, Embryos provide a wildtype (WT) environment to determine tissue-specific differentiation (upper left). Derived by diploid aggregations, ES stochastically contribute to tissue patterning with diffuse integration tracked with constitutively labelled EF-lacZ cell line (upper right) and cardiac-specific integration identified by α-MHC-lacZ reporter (lower left). iPS, labeled with ubiquitously expressing reporter with CMV promoter, identifies progeny throughout developing embryo (lower right). D, Chimerism with lacZ-labeled iPS demonstrated robust contribution to developing hearts within 9.5 dpc embryos. Bar = 100 µm. E, Heart parenchyma of 9.5 dpc chimeric embryo contained integrated iPS progeny expressing β-galactosidase. Bar = 50 µm.

Figure 19. iPS fate determined by host competency. A, Subcutaneous injection of 500,000 iPS in immunodeficient host resulted in tumor growth (dotted circle). B, Upon acute myocardial infarction, 200,000 iPS transplanted intra-myocardially were detected in the heart region by in vivo bioluminescence imaging dramatically expanding by 4 weeks (wks). C, Tumor growth was detected by echocardiography (upper left) and confirmed on necropsy in all
immunodeficient hosts (upper right). Histology demonstrated tumor expansion outside of the heart (lower left), and infiltration within the wall of infarcted myocardium (lower right). D, Immunocompetent hosts reproducibly averted tumor growth upon subcutaneous injection (square) of 500,000 iPS throughout follow-up. E, iPS transplantation within infarcted myocardium of immunocompetent hosts produced stable engraftment detected by live-cell imaging throughout the 4 week follow-up. F, Post-ischemic myocardium transplanted with iPS at 4 weeks demonstrated rare pockets of SSEA-I positive progeny. Bar = 10 µm. G, Subcutaneous (sc) transplantation produced teratoma in immunodeficient (deficient), in contrast to tumor-free outcome in all immunocompetent (competent) hosts. H, Normal pre-infarction (Pre) sinus rhythm was maintained following iPS transplantation throughout the 4 week follow-up, with P-waves (triangles) preceding each QRS complex (stars) with no ventricular tachycardia or ectopy.

Figure 20. iPS restored function following acute myocardial infarction (MI). A, Upon randomization, cell-based intervention was performed at 30 minutes after coronary ligation. Divergent ejection fractions were noted in iPS (n=6) versus fibroblast (n=6) treated hearts within 1 week post-therapy, maintained throughout follow-up. *p=0.002 using two-way repeated measures ANOVA. B, Fractional shortening was similar at day 1 post-infarction, but significant improvement was only observed in iPS-treated hearts. Line indicates median value. *p=0.01. C, Septal wall thickness was preserved in systole following iPS (n=6) compared to fibroblast (n=6) treatment. *p=0.006. D, Echocardiography with long-axis views revealed anterior wall thinning and apex aneurysmal formation (arrow heads) in fibroblast-treated hearts as indicated by akinetic wall (left) in contrast to normalized systolic wall motion in iPS-treated hearts (right). E, Short-axis confirmed thinning in the anterior wall (black bar) and overall decreased cardiac performance with fibroblast compared to iPS-based interventions. The larger and smaller dotted lines indicate endocardium and epicardium, respectively. LVVd: left ventricular volume in diastole; LWs: left ventricular volume in systole.

Figure 21. iPS halt maladaptive remodeling and preserve structure. A, Diastolic parameters revealed a significant decrease in global left ventricular diastolic diameter (LVDd) in hearts treated with iPS (n=6) compared to fibroblasts (n=6) at 4-weeks post-therapy (*p=0.007). B, M-mode echocardiography demonstrated dilated ventricular lumen with reduced anterior and septal wall thickness (SWTd) during systole in fibroblast-treated hearts (upper), which improved
with iPS intervention (lower). C. Time required for ventricular repolarization and depolarization, measured by the QT interval, was significantly prolonged in fibroblast (n=6) compared to iPS (n=6) treated hearts. *p=0.004. D. Hearts were pathologically enlarged in the fibroblast-treated group with aneurysmal formation (+) and severe wall thinning (+) visible with transillumination compared to structurally preserved iPS-treated hearts with normal apex geometry (-) and opaque thick walls (-) on right anterior-oblique (RAO) view upon transverse sectioning of hearts immediately inferior to the site of surgical ligation (dotted line). Bar = 5 mm. Aneurysm delineated by yellow dotted circle. RA: right atrium; LA: left atrium; LV: left ventricle; s: suture; SWTd: septal wall thickness in diastole; SWTs: septal wall thickness in systole; PWTd: posterior wall thickness in diastole; PWTs: posterior wall thickness in systole.

Figure 22. iPS treatment reduced scar and contributed to multi-lineage reconstruction. A, After 4 week of therapy, Masson's trichrome staining demonstrated reduced anterior wall thickness (AWT) and fibrosis in hearts treated with fibroblasts (left) compared to iPS (right). B, Autopsy demonstrated tumor-free heart, liver, lung, or spleen in the iPS-treated cohort. C, After 4 weeks, integrated iPS progeny expressed markers of remuscularization according to α-actinin (right) and β-gal co-expression (arrow heads), not detectable with fibroblast treatment (left). D, Smooth muscle actin (α-SMA; arrow head), and E, CD31 positive endothelium (arrow heads) were identified in iPS progeny (right) compared to no expression with fibroblast treatment (left). DAPI visualized nuclei. Bar = 5 µm.

Figure 23. The H87Q capsid substitution in vector packaging constructs increases HIV vector infectivity across species. (A) Naturally occurring capsid substitutions were introduced into the cyclophilin A-binding region of HIV-1 gag gene of a vector packaging construct, p8.9Ex. Infectious HIV vectors were generated by packaging a GFP-carrying HIV vector genome with the modified constructs, and the amounts of vectors were normalized by the levels of endogenous reverse transcriptase (RT) activity in vector particles. Human, simian, and murine cell lines were infected with various amounts of GFP-expressing vectors, and GFP-positive cell populations were analyzed by flow cytometry. Vector infectivity in each target cell line was determined by infectious units per nanogram RT activity. (B) GFP-carrying HIV vectors were generated with a conventional HIV packaging construct (p8.9Ex) or a packaging construct with the H87Q capsid substitution (pEx-QV). MEFs (5 x 10⁴) were infected with increasing amounts of unconcentrated vectors. The percentage of transfected cells was observed by
comparing total cells to GFP-positive cells under UV microscope three days after infection (left panels, with 20 µL of vector input) and analyzed by flow cytometry five days after vector infection (right panel).

Figure 24. Efficient expression of sternness-associated factors in human and murine cell types. (A) Percent amino acid homology among orthologous sternness-related factors. Homology for LIF served as benchmark. Homology was determined by LALIGN program (EMBNet). NA = protein sequence not available. (B) Scheme of the HIV-I vector genome construct used to generate sternness factor-expressing vectors. Ψ = packaging signal; LTR = long terminal repeat; RRE = Rev-responsive element; cPPT = central polypurine tract; SFFV = spleen focus-forming virus promoter; WPRE = Woodchuck hepatitis virus posttranscriptional regulatory element. OCT-3/4, SOX2, KLF4, and c-MYC cDNAs were driven by an internal SFFV promoter. The KLF4-encoding vector lacks WPRE. (C) 293T cells (2 x 10^5) were infected with 50 µL of the sternness factor-expressing vectors. Three days after infection, expression of full-length sternness factors was verified by Western blotting with respective antibodies. (D) MEFs (5 x 10^4) were infected with 100 µL of unconcentrated vectors. Expression levels of transgene products were visualized by immunostaining four days following infection.

Figure 25. Transduced murine fibroblasts with human sternness factors reactivate stem cell phenotype. (A) Control virus expressing GFP demonstrated no discernible changes in MEF morphology. (B) Coinfection with human OCT-3/4, SOX2, KLF4, and c-MYC vectors produced multiple colonies with distinct stem cell-like morphology that allowed isolation of individual clones. (C) Native MEFs continued to grow in monolayer and displayed contact inhibition at confluence. (D) Clonal expansion of transduced cells demonstrated morphology similar to embryonic stem cells. (E, F) Both native and transduced MEFs expressed markers of cell cycle activation indicated by Ki67 (cyan) in a subpopulation of progeny. (C, H) The stem cell marker SSEA1 was uniquely expressed within transduced cells compared with native MEFs identified by nuclear staining with DAPI.

Figure 26. Gene expression following in vitro differentiation recapitulates gastrulation. (A) Differentiation of transduced cells was facilitated by three-dimensional clustering in a hanging drop to allow spontaneous maturation over a 5-day time course. (B) Pluripotency markers, OCT4, SOX2, and FGF4, were highest in transduced cells at day 0 of differentiation,
compared with either native MEFs or transduced counterparts at day 5 post initiation of
differentiation. (C) The markers of mesoderm (Gsc), endoderm (Sox17), and ectoderm (Zicl)
were higher after five days of differentiation compared with day 0 of differentiation.

Figure 27. Multilineage in vivo differentiation within tumors. (A) Spontaneous in vivo
differentiation was monitored in immunodeficient mice following subcutaneous injection by
comparing native and transduced MEFs. (B) Tumor growth was detected only from sites injected
with transduced cells after 1-2 weeks, followed by rapid expansion of tumor bulk, absent from
native MEF injection sites. (C-F) Tissue was harvested at 4-6 weeks post injection.
Cryosections and tissue staining demonstrated multiple lineages within the complex architecture
of the nascent tumor and included muscle, keratin, glandular epithelium, and poorly
differentiated tissues.

Figure 28. Transduced cells integrate into host morula. (A, B) Transduced MEFs were
labeled with GFP tag for tracking and allowed selection for ex utero integration into early-stage
embryos. (C) Diploid aggregation between labeled transduced cells and normal morula
produced chimeric early embryos. (D) Chimeric embryos developed into blastocysts, which
displayed proper cavitation and formation of mosaic inner cell mass (ICM) with GFP-labeled
blastomeres.

Figure 29. Organogenesis derived from transduced cells. (A-F) Chimeric embryos were
transferred into a surrogate mother for in utero differentiation and were harvested at 9.5 dpc for
tissue analysis. Confocal microscopy revealed transduced progeny throughout the embryo
including neuronal tissues of the forebrain (A) and hindbrain (B), along with the multilineage
pharyngeal arches that contained endoderm derivatives (C). Mesoderm-derived lineages were
present in the heart (D), limb bud (E), and somites (F).

Figure 30. Bioengineered pluripotency in the absence of c-MYC transgene. A, Mouse
embryonic fibroblasts (left) were transduced with three HIV-derived lentiviruses containing
human genes SOX2, OCT4, and KLF4. Genomic integration of viral constructs was detected in
transduced progeny, but not in parental fibroblast (right). B, Within three weeks, expression of
the gene triad (3F) induced a dramatic change from flat fusiform fibroblasts to a round and
compact embryonic-stem-cell-like morphology (left) with reduced cytoplasm (right). C,
Reprogrammed cells acquired pluripotency markers alkaline phosphatase (AP; left) and SSEA-I
(right), absent from parental fibroblasts (inset).
Figure 31. Validated pluripotency of iPS according to in vivo differentiation. A, Fulfilling increasing levels of pluripotent stringency, 3F-iPS generated teratoma when injected subcutaneously into immunodeficient host. Tissues from the three germinal layers were identified by hematoxylin-eosin staining (40x magnification) represented by glandular epithelium (endoderm), keratinized epidermal ectoderm (ectoderm), and connective tissue (mesoderm). B, Cardiac tissue was found in teratoma derived from 3F-iPS as characterized by hematoxylin-eosin stained striations (left) and immunostaining for cardiac proteins α-actinin (middle), and troponin-I with connexin 43 (right), bar 10 µm. DAPI: 4,6′-diamidino-2-phenylindole.

Figure 32. Kinetics of in vitro lineage derivation from iPS. 3F-iPS were differentiated using the hanging drop method followed by expansion of progeny on gelatinized plates. A, Cells were sampled from undifferentiated cultures at day 0 (top), floating embryoid bodies at day 5 (middle), and differentiating cultures at day 12 (bottom) for gene expression analysis. B, Pluripotency genes Sox2, Oct4, and Fgf4 immediately downregulated with initiation of differentiation. C, Gastrulation markers peaked at day 5, coinciding with three germ layer formation in embryoid bodies. D, Upregulation of cardiac transcription factors Tbx5, Nkx2.5, and Mef2c was observed at day 12 indicating that 3F-iPS are able to produce cardiac progenitors. *p<0.05.

Figure 33. Functional cardiogenesis derived from 3F-iPS. A, Derived from two independently isolated clones, embryoid bodies (EB) increasingly demonstrated beating areas between day 7 and 11 of differentiation. The presence of area actively contracting coincided with positive immunostaining for cardiac protein α-actinin (inset, bar 10 µm). B, Synchronized contractile activity (rectangles; top) was detected within adjacent EB (bottom). C, Electron microscopy of 3F-iPS derived cardiomyocytes (CM) revealed morphological changes from compacted colonies to rod-shaped cardiomyocyte-like cells (top). High density contractile proteins were found in organizing sarcomeres (middle) as well as gap junction structures between adjacent cells (bottom). D, Immunostaining demonstrated presence of contractile protein alpha actinin in combination with cardiac transcription factor Mef2c (top), and gap junction-protein connexin 43 (bottom). E, Action potentials were recorded in beating cells using patch clamp in the current clamp mode. DAPI: 4,6′-diamidino-2-phenylindole.

Figure 34. Calcium-dependent excitation-contraction coupling in 3F-iPS-derived
cardiomyocytes. A, An inward current was detected in iPS-derived cardiomyocytes (3F-iPS CM) absent from parental fibroblasts (Fibroblast). B, Reversal of extracellular calcium suppressed inward current. C, Spontaneous action potentials were reversibly arrested in zero calcium milieu. D, Fluo-4AM labeled iPS-derived cells demonstrated fluorescent dynamics consistent with calcium transients. E, Rhythmic calcium transients coincided with cell contractions.

Figure 35. iPS bioengineered cardiac chimerism contributes to sustained heart function throughout development and lifespan. (A-B) LacZ labeled-iPS coincubated with diploid embryos. (C-D) Chimeras revealed the ability of 3F-iPS to integrate into host morulae. (E-G) Presence of iPS was sustained throughout embryonic development as shown for 8.0 through 9.5 dpc contributing to cardiac inflow and outflow tracts (G, inset). H, Other than mosaic coat color, adult chimeras were physically indistinguishable from non-chimeric littermates. I, Increasing levels of chimeric expressed luciferase distributed within tissues were detected according to molecular imaging with iPS-derived progeny. J, Cardiac electrocardiography was equivalent between non-chimera and chimera. K, Cardiac echocardiography demonstrated normal structure of heart, valves, and great-vessels with equivalent systolic and diastolic function between non-chimera and chimera. Ao: aorta, LV: left ventricle; LVDd: left ventricular diastolic diameter, LVDs: left ventricular systolic diameter, RV: right ventricle, bar 2 mm.

Figure 36 is a bar graph plotting the percent of beating embryoid bodies observed in iPS reprogrammed with four factors (n=2), iPS reprogrammed with three factors (n=2), or embryonic stem cell line (ESC) during day 7 to 11 of differentiation.

DETAILED DESCRIPTION

This document provides methods and materials related to induced pluripotent stem cells. For example, this document provides induced pluripotent stem cells that were induced using polypeptides from a species that is different from the species from which the cells were obtained. An example of such induced pluripotent stem cells includes mouse cells that were induced to form induced pluripotent stem cells using human polypeptides. Other examples include rat, dog, cow, pig, and monkey (e.g., Rhesus monkey) cells that were induced to form induced pluripotent stem cells using human polypeptides. In some cases, an induced pluripotent stem cell provided
herein can be a human cell that was induced to form an induced pluripotent stem cell using non-human polypeptides (e.g., polypeptides of mouse, rat, pig, dog, or monkey origin).

This document also provides induced pluripotent stem cells that were induced using polypeptides from a species that is the same species from which the cells were obtained. An example of such induced pluripotent stem cells includes human cells that were induced to form induced pluripotent stem cells using human polypeptides.

The polypeptides used to induce the formation of induced pluripotent stem cell can include any combination of Oct3/4 polypeptides, Sox family polypeptides (e.g., Sox2 polypeptides), Klf family of polypeptides (e.g., Klf4 polypeptides), Myc family polypeptides (e.g., c-Myc), Nanog polypeptides, and Lin28 polypeptides. For example, nucleic acid vectors designed to express Oct3/4, Sox2, Klf4, and c-Myc polypeptides can be used to obtain induced pluripotent stem cells. In some cases, Oct3/4, Sox2, Klf4, and c-Myc polypeptides can be directly delivered into target cells to obtain induced pluripotent stem cells using a polypeptide transfection method (e.g., liposome or electroporation). In one embodiment, nucleic acid vectors designed to express Oct3/4, Sox2, and Klf4 polypeptides, and not a c-Myc polypeptide, can be used to obtain induced pluripotent stem cells. In some cases, Oct3/4, Sox2, and Klf4 polypeptides can be directly delivered into target cells to obtain induced pluripotent stem cells using a polypeptide transfection method. An Oct3/4 polypeptide can have the amino acid sequence set forth in GenBank® Accession Numbers BC1 17435 (e.g., GI No. 109659099). An Sox2 polypeptide can have the amino acid sequence set forth in GenBank® Accession Numbers BC013923 (e.g., GI No. 33869633). A Klf4 polypeptide can have the amino acid sequence set forth in GenBank® Accession Numbers BC029923 (e.g., GI No. 20987475). A c-Myc polypeptide can have the amino acid sequence set forth in GenBank® Accession Numbers BC000141 (e.g., GI No. 12652778). A Nanog polypeptide can have the amino acid sequence set forth in GenBank® Accession Numbers BC099704.1 (e.g., GI No. 71043476). A Lin28 polypeptide can have the amino acid sequence set forth in GenBank® Accession Numbers BC028566 (e.g., GI No. 33872076).

Any appropriate cell type can be used to obtain induced pluripotent stem cells. For example, skin, lung, heart, liver, blood, kidney, or muscle cells can be used to obtain induced pluripotent stem cells. Such cells can be obtained from any type of mammal including, without limitation, humans, mice, rats, dogs, cats, cows, pigs, or monkeys. In addition, any stage of the
mammal can be used, including mammals at the embryo, neonate, newborn, or adult stage. For example, fibroblasts obtained from an adult human patient can be used to obtain induced pluripotent stem cells. Such induced pluripotent stem cells can be used to treat that same human patient (or to treat a different human) or can be used to create differentiated cells that can be used to treat that same human patient (or a different human). For example, somatic cells from a human patient can be treated as described herein to obtain induced pluripotent stem cells. The obtained induced pluripotent stem cells can be differentiated into cardiomyocytes that can be implanted into that same human patient. In some cases, the obtained induced pluripotent stem cells can be directly administered to that same human patient.

Any appropriate method can be used to introduce nucleic acid (e.g., nucleic acid encoding polypeptides designed to induce pluripotent stem cells from cells) into a cell. For example, nucleic acid encoding polypeptides (e.g., Oct3/4, Sox2, Klf4, and c-Myc polypeptides) designed to induce pluripotent stem cells from other cells (e.g., non-embryonic stem cells) can be transferred to the cells using recombinant viruses that can infect cells, or liposomes or other non-viral methods such as electroporation, microinjection, transposons, phage integrases, or calcium phosphate precipitation, that are capable of delivering nucleic acids to cells. The exogenous nucleic acid that is delivered typically is part of a vector in which a regulatory element such as a promoter is operably linked to the nucleic acid of interest. The promoter can be constitutive or inducible. Non-limiting examples of constitutive promoters include cytomegalovirus (CMV) promoter and the Rous sarcoma virus promoter. As used herein, "inducible" refers to both up-regulation and down regulation. An inducible promoter is a promoter that is capable of directly or indirectly activating transcription of one or more DNA sequences or genes in response to an inducer. In the absence of an inducer, the DNA sequences or genes will not be transcribed. The inducer can be a chemical agent such as a protein, metabolite, growth regulator, phenolic compound, or a physiological stress imposed directly by, for example heat, or indirectly through the action of a pathogen or disease agent such as a virus.

Additional regulatory elements that may be useful in vectors, include, but are not limited to, polyadenylation sequences, translation control sequences (e.g., an internal ribosome entry segment, IRES), enhancers, or introns. Such elements may not be necessary, although they can increase expression by affecting transcription, stability of the mRNA, translational efficiency, or the like. Such elements can be included in a nucleic acid construct as desired to obtain optimal
expression of the nucleic acids in the cells. Sufficient expression, however, can sometimes be obtained without such additional elements.

Vectors also can include other elements. For example, a vector can include a nucleic acid that encodes a signal peptide such that the encoded polypeptide is directed to a particular cellular location (e.g., the cell surface) or a nucleic acid that encodes a selectable marker. Non-limiting examples of selectable markers include puromycin, adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo, G418, APH), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase, thymidine kinase (TK), and xanthin-guanine phosphoribosyltransferase (XGPRT). Such markers are useful for selecting stable transformants in culture.

Any appropriate viral vectors can be used to introduce sternness-related factors, such as Oct3/4, Klf4, Sox2 and c-Myc. Examples of viral vectors include, without limitation, vectors based on DNA or RNA viruses, such as adenovirus, adeno-associated virus (AAV), retroviruses, lentiviruses, vaccinia virus, measles viruses, herpes viruses, baculoviruses, and papilloma virus vectors. See, Kay et al., Proc. Natl. Acad. Sci. USA, 94:12744-12746 (1997) for a review of viral and non-viral vectors. Viral vectors can be modified so the native tropism and pathogenicity of the virus has been altered or removed. The genome of a virus also can be modified to increase its infectivity and to accommodate packaging of the nucleic acid encoding the polypeptide of interest. In some cases, the induced pluripotent stem cells provided herein can be obtained using viral vectors that do not integrate into the genome of the cells. Such viral vectors include, without limitation, adenoviral vectors, AAV vectors, baculovirus vectors, and herpesvirus vectors. For example, cells obtained from a human can be provided nucleic acid encoding human Oct3/4, Sox2, Klf4, and c-Myc polypeptides using viral vectors that do not integrate the exogenous nucleic acid into the cells. Once the polypeptides are expressed and induced pluripotent stem cells are obtained, the induced pluripotent stem cells can be maintained in culture such that the induced pluripotent stem cells are devoid of the exogenous nucleic acid.

Any appropriate non-viral vectors can be used to introduce sternness-related factors, such as Oct3/4, Klf4, Sox2, and c-Myc. Examples of non-viral vectors include, without limitation, vectors based on plasmid DNA or RNA, retroelement, transposon, and episomal vectors. Non-viral vectors can be delivered to cells via liposomes, which are artificial membrane vesicles. The composition of the liposome is usually a combination of phospholipids,
particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations. Transduction efficiency of liposomes can be increased by using dioleoylphosphatidylethanolamine during transduction. See, Feigner et al., *J. Biol. Chem.*, 269:2550-2561 (1994). High efficiency liposomes are commercially available. See, for example, SuperFect® from Qiagen (Valencia, CA).

In some cases, induced pluripotent stem cells can be obtained using culture conditions that do not involve the use of serum or feeder cells. For example, cells obtained from a human can be provided nucleic acid encoding human Oct3/4, Sox2, Klf4, and c-Myc polypeptides and cultured using media lacking serum (e.g., human or non-human serum) and lacking feeder cells (e.g., human or non-human feeder cells).

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

**EXAMPLES**

**Example 1 - Generating mouse and human iPS cells using human stem cell-associated factors**

The following studies were performed to establish effective methods for generating an iPS cell line capable of multilineage differentiation from somatic fibroblasts. These results include generating both mouse and human iPS cells using human stem cell-associated factors.

*Generation of HIV vectors expressing stem cell-related factors.* Human sequences were used to generate reprogramming vector sets that could be tested in evolutionary distant somatic cell types. Human factor cDNAs were amplified by PCR, and the PCR products were cloned into a HIV vector plasmid, pSIN-CSGWdlNotl vector, resulting in HIV-based lentiviral vectors encoding human Oct-3/4, Sox2, Klf4, c-Myc, Nanog, and Lin28. For improved transduction efficiency in mouse and rhesus cells, the modified HIV packaging construct with a H87Q Capsid mutation, pEx-QV, was used to produce infectious HIV vectors. After infection of human 293T cells with the infectious vectors, robust transgene expression was verified by immunoblotting with specific antibodies (Figure 1).

*Ectopic expression ofOct3/4, Sox2, Klf4, and c-Myc in human somatic cells led to*
formation of iPS-like colonies. Human iPS cells form sharp-edged, flat, tightly-packed colonies similar to human ES cells, and express human ES-specific markers (Takahashi et al., Cell, 131:861-72 (2007) and Yu et al., Science, 318:1917-20 (2007)). Human somatic cells (primary cardiac fibroblasts HCF (ScienCell), foreskin-derived fibroblasts BJ (ATCC), fetal lung fibroblasts MRC-5 (ATCC)) were infected with different combinations of lentiviral vectors. Three weeks after co-cultivation with mouse feeder cells, ES/iPS-like colonies were observed in cells infected with Oct3/4, Sox2, Klf4, and c-Myc vectors (Figures 2 and 3), but not in untreated cells or cells treated with vectors expressing Oct3/4, Sox2, Klf4, Nanog, and Lin28 (Figure 3).

Putative human iPS clones express alkaline phosphatase and human ES/iPS-specific markers. Colonies selected for human ES/iPS-like morphology from HCF, BJl and MRC-5 cells were analyzed for alkaline phosphatase expression. Putative iPS clones, which were grown on feeder cells for three days, were fixed for one minute in 2% paraformaldehyde and then stained with the first red violet solution for 15 minutes at room temperature (Millipore, ES cell characterization kit). All putative human iPS clones tested expressed alkaline phosphatase (Figure 4). Colonies also were analyzed by immunohistochemistry, detecting expression of human ES/iPS markers SSEA4, TRA-1-60, and TRA-1-81, but not SSEA1 (Figure 5).

Derivation of putative mouse iPS cells. When mouse embryonic fibroblasts were infected with four HIV vectors expressing human pluripotent genes, numerous (>500) mouse ES/iPS-like colonies were generated (Figure 6). Following one week of co-culture with feeder cells, clonal expansion of selected colonies yielded progeny expressing the stem cell marker SSEA-I (Figure 7). In contrast to the original fibroblast source, derived iPS lines displayed ES-like morphology, and after six passages maintained expression of the pluripotent Oct4/Sox2 genes.

Derivation of mouse iPS-like colonies from adult mouse somatic cells. To test if human iPS-related factors can reprogram adult mouse somatic cells, mouse lung-, kidney-, tail-, and heart-derived cells from a six weeks old B16-GFP transgenic mouse and a factor VIII knockout mouse were infected with HIV vectors expressing human Oct3/4, Sox2, Klf4, and c-Myc. Numerous ES-like colonies were formed ten days after vector infection, especially in the lung-derived cells, and putative iPS clones were successfully expanded on mouse feeder cells.

Expression of gastrulation during in vitro differentiation of iPS-derived embryoid body. In order to verify the pluripotency, the in vitro differentiation potential of the putative iPS cells
was analyzed. An iPS clone was differentiated into embryoid bodies (EB), and the gastrulation markers in undifferentiated iPS cells and EB were examined by RT-PCR. Significant induction of gastrulation markers was evident in EB, indicating derivation of germ layers from transformed fibroblasts (Figure 8).

In vitro differentiation of mouse iPS cells into embryoid bodies capable of rhythmic contractions. The putative iPS cells were tested for the ability to differentiate into cardiomyocytes. iPS-derived embryoid bodies were successfully differentiated into beating cardiomyocytes, evidence of the formation of contractile cardiomyocytes with pacemaker activity.

Mouse iPS cell engraftment into host morula. A MEF-derived iPS clone was labeled with GFP by infecting the cells with a GFP-expressing HIV vector. GFP-labeled iPS cells were efficiently incorporated into developing morula to form a chimera blastocyst, a property limited to genuine ES cells (Figure 9). Mosaic embryos are generated using GFP-labeled iPS cells in diploid aggregation for intrauterine transfer and subsequent embryonic development, and are used to characterize tissue-specific differentiation capacity of engineered iPS cells.

Xenografts of iPS cells in nude mice generate teratoma-like masses. Human and mouse ES cells form teratomas after cell injection into immunodeficient mice, an assay that has become the accepted standard for demonstrating their developmental pluripotency. Immunodeficient mice were subcutaneously injected with mouse iPS clones or parental MEF cells. Injection of 500,000 iPS cells resulted in formation of a subcutaneous tumor that enlarged to 1 cm diameter within 4 weeks (Figure 10). Histology of mass revealed complex cellular architecture consistent with diverse lineage differentiation of a teratoma (Figure 10). Tissue-specific immunostaining is performed to characterize cytotypes fully.

Derivation of putative iPS cells from rat cells. The ability of human iPS-related factors to reprogram rat somatic cells into ES-like progeny was tested. Normal rat kidney cells were infected with HIV vectors expressing human Oct3/4, Sox2, Klf4, and c-Myc. Vector-infected cells were co-cultured with mouse SNL feeder cells for eight days. Many iPS-like colonies were observed, and 12 colonies were picked for further characterization. Only two of the 12 colonies maintained the iPS-like morphology for two weeks in the presence of mouse LIF (Figure 11). iPS-like colonies were also formed in the Chinese hamster cells following transduction by the four human factor-expressing vectors (Figure 11).
Derivation of putative iPS cells from rhesus monkey cells. Rhesus monkey kidney derived cells were infected with HIV vectors expressing human Oct3/4, Sox2, Klf4, and c-Myc. Vector-infected cells were co-cultured with mouse SNL feeder cells for ten days in serum-free media (HuESGro, Millipore) supplemented with human b-FGF. Six putative rhesus monkey iPS clones with sharp-edged, flat and tightly-packed colonies similar to human iPS cells were identified (Figure 11).

These results demonstrate the feasibility of reprogramming of human and mouse cells with defined human factors. For example, these results demonstrate that HIV vectors expressing human Oct3/4, Sox2, Klf4, c-Myc, Nanog, and Lin28 can be used to derive iPS cells from rat, dog, and rhesus monkey cells, thereby allowing appropriate efficacy and toxicology testing of autologous iPS cells in appropriate animal models.

Efficient iPS derivation from experimental animals can enable preclinical efficacy testing of autologous iPS cells in proper models. Use of the vectors expressing human stem cell factors can allow direct toxicology testing of the same vectors used in human trials.

The influence of systemic administration of autologous iPS cells in mice and rats can be examined. For example, autologous iPS cells can be genetically label with Luciferase, GFP, and LacZ with HIV vectors, and their in vivo distribution (examples of live-imaging are shown in Figure 12) can be monitored. Where the cells migrate, how they differentiate in vivo, and whether they form teratomas in immunocompetent hosts can be determined. The biodistribution of iPS cells in healthy and diseased animals can be compared. In addition, the therapeutic effects of autologous iPS injection into myocardial infarction-induced mouse and rat models can be tested. These studies can be expanded in dog, pig, and rhesus monkey heart disease models.

Example 2 - Reprogramming mouse fibroblast cells using lentiviral vectors expressing human Oct3/4, Sox2, Klf4, and c-Myc

The following is performed to further characterize the ability of human factors to reprogram mouse fibroblast cells into iPS cells. Fibroblasts are isolated from a GFP transgenic C57/BL6 mouse tail. 5 x 10⁴ cells are infected with HIV vectors expressing human Oct3/4, Sox2, Klf4, and c-Myc at multiplicity of infection of 10. Transduced cells are cultured in the normal growth medium for fibroblast cells for four days, and then are spread in a 10-cm plate on a mouse SNL feeder cells. One day after the passage, culture supernatants are changed to LIF-
and FCS-containing ES media. One third of the culture supernatants are replaced daily. The cells are monitored for up to 3 weeks. 24 iPS-like colonies are picked up for expansion. The remaining cells on the 10-cm plates are fixed by 4% paraformaldehyde for one min, are treated with freshly prepared first red substrate for AP staining (Millipore) for 15 minutes at room temperature, and then are counted for the number of iPS-like colonies.

The 24 clonal iPS-like cells are expanded, and their authenticity is screened by mouse ES/iPS-specific marker SSEAl and alkaline phosphatase expression. Five iPS-like colonies with strong SSEAl and alkaline phosphatase expression are further characterized to demonstrate the pluripotency. The clones are examined for the telomerase activity (TRAPEZE telomerase kit), in vitro differentiation through embryoid bodies (EB), pluripotency-associated gene expression, and the ability to form teratomas and are used to generate chimeric mice.

*Mouse ES and iPS culture.* Mouse ES and iPS cells are maintained in Glasgow's Minimum Essential Medium (BioWhittaker-Cambrex) supplemented with pyruvate and L-glutamine (Cellgro), non-essential amino acids (Cellgro), β-mercaptoethanol (Sigma-Aldrich), 10% FCS (Invitrogen), and leukemia inhibitory factor (Chemicon International).

*EB formation.* Mouse iPS cells are differentiated into three-layer embryoid bodies using the hanging-drop method in differentiation media supplemented with 20% FCS and TNF-α (Invitrogen) as described elsewhere (Nelson et al., *Stem Cells*, 26:1464-73 (2008)). In vitro differentiation of mouse iPS cells into embryoid bodies capable of rhythmic contractions is performed as described elsewhere (Nelson et al., *Stem Cells*, 26:1464-73 (2008)).

*Cells.* 293T (ATCC), MRC-5 (ATCC), BJ (ATCC) and SNL feeder cells (MMRRC) are maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FCS and antibiotics. Primary mouse, rat, dog, and pig fibroblast cells are cultured in DMEM supplemented with 10% fetal calf serum (FCS) and antibiotics.


*Immunostaining.* Immunostaining to detect cell surface markers is performed as described elsewhere (Noser et al., *Mol. Ther.*, 15:1531-6 (2007) and Palmowski et al., *J.*
Example 3 - Reprogramming somatic cells from rat, dog, pig, and rhesus monkey cells

The following is performed to further characterize the generation of iPS cells from diverse species with vectors expressing defined human stem cell-related factors. Rat and pig lung-derived primary cells (less than 5 passages) and dog cardiac fibroblast cells are used to derive rat, dog, and pig iPS cells. Rhesus monkey lung-derived fibroblast cells (DBL-FRhl-2, ATCC CL-160), fetal epithelial cells (FrhK4, ATCC CRL-1688), primary peripheral blood monocytes (Dr. DeRavin, NIAID) and primary hepatocytes (Celsis Invitro Technologies) are used to derive iPS cells from rhesus monkey. 5 x 10^4 cells are infected with various combinations of HIV vectors expressing human Oct3/4, Sox2, Klf4, c-Myc, Nanog, and Lin28 at multiplicity of infection of 10. Transduced cells are cultured in the normal growth medium for fibroblast cells for 4 days, and then are spread in a 10-cm plate on a mouse SNL feeder cells. One day after the passage, the medium is changed to specific ES media (Table 1). For rat iPS cell derivation, mouse ES media supplemented with 1000 units of rat LIF (Millipore) is used. For dog and pig iPS cell derivation, mouse ES media supplemented with mouse LIF (Chemicon International) and human LIF (Millipore) are used, respectively. For rhesus monkey iPS cells, b-FGF-containing HuESGrO medium is used. One third of the culture supernatants are replaced daily. The cells are monitored for up to 3 weeks. 24 iPS-like colonies are picked up for expansion. The remaining cells on the 10-cm plates are fixed by 4% paraformaldehyde for 1 minute, treated with freshly prepared first red substrate for AP staining (Millipore) for 15 minutes at room temperature, and then counted for the number of iPS-like colonies.
Table 1. ES Cell Markers and cytokines used to maintain the cells.

<table>
<thead>
<tr>
<th></th>
<th>Mouse</th>
<th>Rat</th>
<th>Dog</th>
<th>Pig*</th>
<th>Cow*</th>
<th>Rh</th>
<th>Hu</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSEA1</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSEA-3</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSEA-4</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRA-1-60</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRA-1-81</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct4</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>APTase</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Growth factor</td>
<td>mLIF</td>
<td>mLIF</td>
<td>mLIF</td>
<td>hLIF</td>
<td>hLIF</td>
<td>hLIF</td>
<td>bFGF</td>
</tr>
<tr>
<td></td>
<td>mLIF</td>
<td>mLIF</td>
<td>mLIF</td>
<td>hLIF</td>
<td>hLIF</td>
<td>hLIF</td>
<td>bFGF</td>
</tr>
</tbody>
</table>

* Porcine and Bovine ES-like cells

The 24 clonal iPS-like cells are expanded, and their authenticity screened by mouse ES/iPS-specific marker and alkaline phosphatase expression. Five iPS-like colonies with strong SSEA1 (SSEA4 for rhesus iPS cells) and alkaline phosphatase expression are further characterized to demonstrate the pluripotency. The clones are examined for the telomerase activity (TRAPEZE telomerase kit), in vitro differentiation through EB, pluripotency-associated gene expression, and teratoma formation.

Rat, dog, and pig iPS culture. Mouse ES/iPS media is used with rat LIF, human LIF, or mouse LIF for rat, dog, and pig iPS cells, respectively.

Rhesus monkey iPS culture. Human iPS cells are maintained in serum-free HESGro medium (Millipore) supplemented with basic fibroblast growth factor (8 ng/mL).

Cells. 293T (ATCC), MRC-5 (ATCC), BJ (ATCC) and SNL feeder cells (MMRRC) are maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% FCS and antibiotics. Primary mouse, rat, dog, and pig fibroblast cells are cultured in DMEM supplemented with 10% fetal calf serum (FCS) and antibiotics.

**Immunostaining.** Immunostaining to detect cell surface markers is performed as described elsewhere (Noser et al., Mol. Ther., 15:1531-6 (2007) and Palmowski et al., J. Immunol, 172:1582-7 (2004)).

**Example 4 - Generating iPS cells without using mouse feeder cells and fetal calf serum**

iPS-like colonies were formed when HCF, BJ, and MRC-5 cells were infected with HIV vectors expressing Oct3/4, Sox2, Klf4, and c-Myc and simply maintained in a serum-free media (HESGro, Millipore, containing b-FGF) for two weeks (Figure 13, upper left panel). iPS clones were successfully expanded on inactivated human MRC-5 cells. These mouse feeder cell-free human iPS cells expressed human iPS/ES markers including alkaline phosphatase, SSEA4, TRA-1-60, and TRA-1-81 (Figure 13). When a modified medium (100 mL of HESGro media plus 25 mL of mTeSRtm (Stem Cell Technologies)) was used, human iPS cells could be derived and expanded without using feeder cells and fetal calf serum (not shown). These results demonstrate that iPS cells for clinical applications can be generated without using mouse feeder cells and fetal calf serum.

**Example 5 - Determining optimal intracellular environment for efficient production of iPS cells**

Ectopic expression of pluripotent genes can rely on the host environment to achieve reprogramming of a non-stem into a stem cell phenotype. To secure optimal induction of pluripotent reprogramming, the influence of the intracellular background environment on the efficiency of iPS generation can be delineated amongst target somatic cells. iPS cells are derived from various murine and human somatic cell lines originating from different tissues and different age groups, and the most efficient cell source for iPS generation is determine. In order to verify pluripotent outcome, putative iPS cell clones are characterized by the following criteria: (i) degree of expression of pluripotent markers (e.g., human SSEA-4, TRA-1-60 and TRA-1-81; mouse SSEA-1); (ii) extent of telomerase activity (i.e., TRAPEZE telomerase kit); (iii)
propensity for *in vitro* and *in vivo* three germinal layer formation (e.g., embryoid body generation); (iv) completeness *in utero* organogenesis (i.e., hybrid iPS/blastomere development for mouse iPS cells); and (v) robustness of tissue-specific differentiation (e.g., cardiomyocytes). Ranking of cytotypes based on the listed criteria is used to determine the optimal intracellular environment for efficient production of iPS cells.


Comparison of benchmarked ES cell transcriptomes with iPS-derived cytotypes is performed in order to reveal the roadmap for effective reprogramming of somatic tissues and advance safe iPS derivation strategies without activation of oncogenic networks that can increase long-term risk of uncontrolled growth.

5 x 10^4 cells derived from skin, bone marrow, heart, lung, kidney, and liver of B16-GFP transgenic mice at different ages (new born, 6 weeks old, and 1 year old) are transduced with HIV vectors expressing Oct3/4, Sox2, Klf4, and c-Myc at multiplicity of infection of 10. Primary human cardiac fibroblasts, hepatocytes, neonate, and adult dermal fibroblasts and mesenchymal stem cells (ScienCell) are also transduced. The transduced cells are cultured in the specific growth media for 4 days, and are spread in a 10-cm plate on SNL feeder cells. The medium is changed to LIF- and FCS-containing media for mouse iPS generation, while serum-free growth media with b-FGF is used for human iPS derivation. One third of the culture supernatants is replaced daily. The cells are monitored for up to 4 weeks, and the number of iPS-like colonies on the plates is counted. The colonies are expanded, and iPS clones are obtained from each group. Their authenticity is verified by surface marker expression. Skin-derived mouse iPS clones from different age groups and iPS clones from different tissues of a 6 week-old
mouse (2 clones/group), as well as human iPS clones from different primary tissues are further characterized as shown in Table 2.

Table 2. Experiments performed to characterize iPS cells in Aims 1 and 2

<table>
<thead>
<tr>
<th></th>
<th>iPS/ES-specific surface markers</th>
<th>Expression of stem cell genes</th>
<th>Telomerase activity</th>
<th>in vitro differentiation</th>
<th>Teratoma Formation</th>
<th>Chimeric animals</th>
<th>Transcriptomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st generation</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>2nd generation</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

Clonal expansion of iPS cells can produce a homogenous cell population amendable to transcription profiling using genome-wide analysis. Transcriptome profiling of parental cytotype in comparison to progenitor cells at sequential stages of reprogramming is achieved during iPS cellular induction. Mouse embryonic fibroblasts are profiled according to transcriptome expression and are used as a reference point to compare iPS-like clones identified by characteristic morphology upon ectopic gene expression. To identify subtle expression network changes predictive of safe and effective reprogramming, iPS-like clones with and without transient expression of oncogenes such as c-Myc are compared to traditional ES cell lines through mRNA isolation, microarray data collection, and bioinformatics network analysis.


**Gene Expression Profiling.** Gene expression changes of microarray data acquired using the GeneChip Scanner 3000 (Affymetrix, Inc, Santa Clara, CA) are profiled with the Genespring GX 7.3 analysis software suite (Agilent Technologies). The derived gene list is limited to report
transcripts with expression levels above background and then is subjected to 1-way ANOVA, using a Benjamini-Hochberg post hoc multiple testing correction for all P<0.01. Differentially expressed genes (P<0.05) are excluded from subthreshold transcripts using Volcano plot analysis, according to a minimum 1.5-fold change, and ontologically dissected to determine physiological system priority emphasized within changing transcripts. Molecular interactions of expression profiles comprising pluripotent gene expression are examined and formatted for Cytoscape 2.2, which provides an ad hoc network map of integrated up- and downregulated candidate genes driving the pluripotent switch.

Example 6 - Establishing genomic modification-free technology for safe production of iPS cells

Retroviral or lentiviral vector integration has risks associated with insertional mutagenesis. Use of oncogenic c-Myc during reprogramming is also problematic for clinical application of the resulting iPS cells, as sustained c-Myc expression can increase the risk of tumor formation in iPS-derived cells in vivo. In order to avoid these risks, iPS cells can be generated without integrating vectors and continuous c-Myc expression. Derivation of iPS cells with transient expression from non-integrating vectors can solve both problems, as the resulting iPS cells carry no genomic modifications.

Since retroviral promoters are rapidly silenced in mouse or human ES cells (Wolf & Goff, Cell, 131:46-57 (2007)), expression of stem cell factors from the introduced retroviral vectors was also silenced in iPS cells (Takahashi et al., Cell, 131:861-72 (2007)). This observation indicates that the stem cell factors are only required to initiate the reprogramming step, but are not mandatory to maintain the resulting iPS phenotype.

It is hypothesized that initiation of the reprogramming step by non-integrating vectors is sufficient to generate iPS cells. To test this hypothesis, and improve upon the iPS derivation strategy, a genomic modification-free strategy for iPS generation is developed. As non-integrating vectors, AAV and integrase-negative HIV vectors are used (Figures 14 and 15). AAV-based vectors are particularly attractive for future clinical applications, as AAV-based vectors can be used under biosafety level 1 practice.

HIV-based vectors generally integrating into host genome before they express significant levels of transgene products. However, recent studies have shown that HIV-based vectors generated with a packaging construct with non-functional viral integrase can express transgene

An additional risk with iPS preparation is the current use of animal-derived biological reagents that preclude clinical grade production and utilization in practice. iPS colonies are established in the absence of fetal calf serum and mouse feeder cells. After successful reprogramming of human somatic cells by non-integrating vectors, genetic modification-free iPS cells are established without using FCS and mouse feeder cells.

Non-integrating HIV vectors expressing human stem cell-related factors are generated using a packaging construct with mutations in the viral integrase (Saenz et al., *J. Virol.*, 78:2906-20 (2004)). The vectors are concentrated about 100-fold by ultracentrifugation as described elsewhere (Strang et al., *Gene Ther.*, 11:591-8 (2004) and Strang et al., *J. Virol.*, 79:1765-71 (2005)). AAV serotypes 2 and 9 vectors expressing the four human factors Oct3/4, Sox2, Klf4 and c-Myc are generate. AAV vectors are concentrated and are purified through ultracentrifugation through cesium chloride gradients. Transgene expression in the cells infected by 10 µL of the concentrated non-integrating HIV and AAV vectors is verified. 5 x 10^4 human skin-derived and cardiac fibroblast cells and mouse tail-derived fibroblasts are consecutively infected with 200 µL of concentrated vectors for 3-14 days. The transduced cells are cultured in the specific growth media for the first 4 days, and are spread in a 10-cm plate with inactivated SNL feeder cells. The medium is changed to LIF- and FCS-containing mouse ES media for mouse iPS generation, while serum-free growth media with 40 ng/mL of b-FGF is used for human iPS derivation. One third of the culture supernatants is replaced daily. The cells are monitored for up to 4 weeks, and the number of iPS-like colonies on the plates is counted.
Obtained iPS-like colonies are isolated to confirm absence of vector integration by sensitive Q-PCR and FISH methods. Representative iPS clones are characterized for their pluripotency as described herein, and the transcriptomes between the iPS made with or without integrating vectors are compared. In order to demonstrate increased safety, iPS-derived chimeric mice are generated using mouse iPS cells made with or without integrating vectors (two clones each), and their respective long-term risk of tumorigenicity is compared.

Mitotically inactivated MRC-5, HCF, and BJ cells are tested to determine whether they can support prolonged undifferentiated growth of human iPS cells. It is determined whether iPS cells can be generated by using autologous human cells as feeders. Genomic modification-free iPS cells are generated by using autologous human cells as feeders.

**Primary mouse cells.** B16-GFP transgenic mice were obtained from Dr. Richard A. Vile (Mayo Clinic). Bone marrow, skin, heart, lung, stomach, spleen, kidney, liver, and tail is harvested, and tissue-derived primary cell cultures are established as described elsewhere (Noser et al, J. Virol, 80:7769-74 (2006); Strang et al, J. Virol, 79:1765-71 (2005); and Relander et al, Mol Ther., 11:452-9 (2005)). Cells are transduced by HIV vectors, and iPS generation efficiency is monitored.

**Mouse ES and iPS culture.** Mouse ES and iPS cells are maintained in Glasgow's Minimum Essential Medium (BioWhittaker-Cambrex) supplemented with pyruvate and L-glutamine (Cellgro), non-essential amino acids (Cellgro), β-mercaptoethanol (Sigma-Aldrich), 10% fetal calf serum (FCS) (Invitrogen), and leukemia inhibitory factor (Chemicon International).

**Primary human cells.** Primary cardiac fibroblasts, pulmonary fibroblasts, hepatocytes, neonate and adult dermal fibroblasts, and mesenchymal stem cells (ScienCell) are cultured in specific media (ScienCell) and are used for iPS induction.

**Human iPS culture.** Human iPS cells are maintained in serum-free HuESGro medium (Millipore) supplemented with basic fibroblast growth factor (40 ng/mL).

**EB formation.** Mouse iPS cells are differentiated into three-layer embryoid bodies using the hanging-drop method in differentiation media supplemented with 20% FCS and TNF-α (Invitrogen) as described herein. *In vitro* differentiation of mouse iPS cells into embryoid bodies capable of rhythmic contractions are performed as described herein.

**Cell lines.** 293T (ATCC), MRC-5 (ATCC), BJ (ATCC), and SNL feeder cells
(MMRRC) are maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FCS and antibiotics.


**AAV vector.** Helper-free AAV vectors based on AAV serotypes 2 and 9 are generated by transient transfection of 293T cells with pHelper, pRepCap, or pRep2Cap9 and pAAV-MCV-derived vector constructs (Stratagene).

**Immunoblotting.** Immunoblotting is performed to detect Oct3/4, Sox2, Klf4, c-Myc, Nanog, and Lin28 as described herein.

**Immunostaining.** Immunostaining is performed to detect cell surface markers as described herein.


**Gene Expression Profiling.** Gene expression changes of microarray data acquired using the GeneChip Scanner 3000 (Affymetrix, Inc, Santa Clara, CA) are profiled with the Genespring GX 7.3 analysis software suite (Agilent Technologies). The derived gene list is limited to report transcripts with expression levels above background and then is subjected to 1-way ANOVA, using a Benjamini-Hochberg post hoc multiple testing correction for all P<0.01. Differentially
expressed genes (P<0.05) are excluded from subthreshold transcripts using Volcano plot
analysis, according to a minimum 1.5-fold change, and ontologically dissected to determine
physiological system priority emphasized within changing transcripts. Molecular interactions of
expression profiles comprising pluripotent gene expression are examined and formatted for
Cytoscape 2.2, which provides an ad hoc network map of integrated up- and downregulated
candidate genes driving the pluripotent switch.

Achieving efficient and safe iPS derivation provides an essential platform for realizing
individualized cell therapy. For clinical iPS application, a further understanding of the influence
of intracellular environment on the reprogramming efficiency is helpful. The studies provided
herein can be extended into broad ranges of human populations including young and old, healthy
and diseased donors. Reprogramming efficiency can be lower from older and diseased donors.
If this is the case, further optimization of the gene transfer vectors, combination of defined stem
cell factors, and vector transduction conditions can be used to improve the reprogramming
efficiency particularly from old and diseased subjects. Through this approach, disease-specific
iPS libraries can be generated. Such patient-specific iPS libraries can provide a valuable
platform to study patient-specific disease development mechanisms in vitro. They can also
increase the efficiency of patient-specific drug discovery. Thus, the methods and materials
provided herein can be used for autologous iPS-mediated cell therapies as well as for tools to
assess patient-specific disease development, drug screening, and drug toxicity (Figure 16).

Example 7 - Repair of acute myocardial infarction with iPS induced
by human sternness factors

Transduction

pSIN-CSGwldNotl-derived transfer vectors were generated with human OCT3/4, SOX2,
KLF4 and c-MYC cDNAs (Open Biosystems; Nelson et al. Clin. Translation Sci., 2:1 18-126
(2009)). The packaging plasmid, pCMVR8.91, was engineered with H87Q mutation in the HIV-
1 capsid region for increased transduction efficiency of purified infectious supernatants (Nelson
embryos at 14.5 days post-coitum (dpc), were expanded in maintenance medium containing
Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal calf serum
(FCS), 1% L-glutamine (Invitrogen) and 1% penicillin/streptomycin, and plated at 10^5/24-wells
prior to transduction for 12 hours with infectious supernatants. Transduced fibroblasts were replated at confluence, and iPSS were isolated in 2 weeks for clonal expansion. Cells were labeled with HIV vectors carrying LacZ (pLenti6/UbC/V5-GW/LacZ, Invitrogen) or luciferase (pSIN-Luc) (Hasegawa et al., *Clin. Cancer Res.*, 15:6170-6178 (2006)).

### Pluripotent induction

R1-derived embryonic stem cells and iPSS were expanded in embryonic stem cell media. Cells were fixed with 3% paraformaldehyde, permeabilized, and stained with anti-SSEA-1 antibody (MAB4301; dilution 1:50; Chemicon) along with secondary goat anti-mouse Alexa Fluor 568 (1:250; Invitrogen). Nuclei were labeled with 4,6'-diamidino-2-phenylindole (DAPI; Invitrogen). For ultrastructural evaluation, cells were examined on Hitachi 4700 field emission scanning or JEOL 1200 EXII transmission electron microscopes (Perez-Terzic et al., *Nat. Clin. Pract. Cardiovasc. Med.*, 4(Suppl. 1):S68-S76 (2007)). Growth and differentiation potential were determined upon subcutaneous injection in anesthetized (2-3% isoflurane) athymic nude mice. Cryopreserved tissue was processed for hematoxylin/eosin procedures (Yamada et al., *Stem Cells*, 26:2644-2653 (2008) and Behfar et al., *J. Exp. Med.*, 204:405-420 (2007)).

### Differentiation

iPSS were differentiated into embryoid bodies using the hanging-drop method (Behfar et al., *FASEB J.*, 16:1558-1566 (2002)). Expression of pre-cardiac mesoderm and cardiac differentiation markers was detected by RT-PCR. Total RNA was extracted with a combination of gDNA Eliminator and RNeasy columns (Qiagen). cDNA was prepared from RNA samples using Superscript III First Strand Synthesis System (Invitrogen). Mouse GAPDH (4352932E; Applied Biosystems) was used as control. Analyzed genes included Gata4 (Mm00484689_ml), Myocd (Mm00455051_ml), and Mef2c (Mm01340839_ml; Applied Biosystems).

### Diploid aggregation

Contribution to embryonic development was assessed through diploid aggregation (Nelson et al., *Phil. Trans. R. Soc. B.*, 364:269-276 (2009)). Host embryos from CD-I superovulated females were collected at 2.5 dpc. Fibroblasts or iPSS were partially digested using trypsin 0.25%-EDTA (Invitrogen), and 8-15 cell clumps were placed with paired embryos.
denuded of zona pellucida. The aggregation complex was incubated for 24 hours (in 5% CO₂/5% O₂/90% N₂) until blastocyst cavitation (Nelson et al., Phil. Trans. R. Soc. B., 364:269-276 (2009)). Chimeric embryos were transplanted into anesthetized (2-3% isoflurane) pseudopregnant surrogate CD-I mothers, harvested at 9.5 dpc, and analyzed for distribution of LacZ-labeled progenitors (Nelson et al., Phil. Trans. R. Soc. B., 364:269-276 (2009)).

**iPS therapy**

Male, 8-12 weeks old C57BL/6 or athymic nude mice were anesthetized (1.5-2% isoflurane), intubated (Mini Vent 845, Hugo Sacks Electronik), and left coronary artery ligated with a 9-0 suture under direct visualization following minimally invasive thoracotomy. Myocardial ischemia was confirmed by electrocardiography, echocardiography, and color change of left ventricular wall. Fibroblasts or iPS (200,000/10 µL of differentiation medium) were transplanted with four injections of 2.5 µL within 30 minutes after ligation. Cryosections (7 µm-thickness) were processed for hematoxylin/eosin, Masson's trichrome, luciferase and β-gal staining (Yamada et al, Stem Cells, 26:2644-2653 (2008) and Behfar et al., J. Exp. Med., 204:405-420 (2007)). Sections were labeled with luciferase (1:5000, Sigma) or β-galactosidase antibody (1:5000, Abeam) coupled with Alexa-568 secondary antibody (1:1000, Invitrogen) and co-localized with α-actinin (1:200, Sigma), smooth muscle actin (1:200, Abeam), CD31 (1:200, Abeam), or SSEA-I (1:50, Chemicon) antibodies all paired with Alexa-488 antibody (1:1000, Invitrogen).

**Live cell imaging and heart performance**

Luciferase-transfected fibroblasts or iPS were cultured for multiple passages including a freeze/thaw cycle prior to expansion and transplantation. Cells were tracked with the IVIS 200 Bioluminescence Imaging System (Xenogen) following intra-peritoneal injection of 150 mg/kg D-luciferin (Xenogen), and signals analyzed with the Living Image Software (Xenogen). Ventricular performance was quantified by echocardiography (RMV-707B scanhead, Vevo770, Visual Sonics). Ejection fraction (%) was calculated as [(LVVd - LVVs)/LVVd] x 100, where LVVd is left ventricular end-diastolic volume (µL) and LVVs, left ventricular end-systolic volume (µL). Left ventricular fractional shortening (% FS) was calculated as [(LVDd - LVDs)/LVDd] x 100, where LVDd is left ventricular end-diastolic dimension (mm) and LVDs,
left ventricular end-systolic dimension (mm) (Yamada et al., Stem Cells, 26:2644-2653 (2008)). Electrical activity was monitored by electrocardiography (MP150, Biopac). Data was collected and analyzed by blinded investigators.

5 **Statistical analysis**

Results are presented as mean ± SEM. Median is additionally reported when grouped data were compared with nonparametric Mann-Whitney U test. Comparison between groups over time was performed by two-way repeated-measures ANOVA. Kaplan-Meier analysis was applied with log-rank testing. p<0.05 was predetermined as significant, and all values >0.001 were reported.

**RESULTS**

*Nuclear reprogramming resets primitive morphology and unlocks functional pluripotency.*

Transduced with human sternness factors, OCT3/4, KLF4, SOX2 and c-MYC, reprogrammed fibroblasts were isolated according to compact clusters of embryonic stem cell-like morphology distinct from monomorphic, single-cell layers of parental fibroblasts (Figure 17A). Reprogrammed cells displayed distinct sub-cellular architecture, reorganized from original fibroblasts to recapitulate salient features of undifferentiated embryonic stem cells with high nucleo/cytoplasmic ratio, predominance of nuclear euchromatin, and scant density of cytosolic organelles (Figure 17B). Reprogramming induced expression of the early embryonic SSEA-I antigen, an initial marker of sternness absent in parental fibroblasts (Figure 17C). To determine functional pluripotency, the inherent capacity for embryonic integration was probed by diploid aggregation using a pair of denuded host embryos (Figure 17D, upper). While morula-derived blastomeres incorporated into an embryonic structure after 24 hours in micro-wells, fibroblasts aborted engraftment and failed to contribute to *ex utero* blastocyst development (Figure 17D, lower left). In contrast, reprogrammed fibroblasts demonstrated spontaneous integration and contributed to pre-implantation blastocyst formation (Figure 17D, lower right).

Non-coerced assimilation into early stage embryos thereby established bona fide iPS clones, providing a high-stringency quality control measure for functional pluripotency.

*Chimeric embryos authenticate iPS-derived patterning of normal cardiogenesis.*
As iPS differentiated within 5-day-old embryoid bodies (Figure 18A), up-regulation of pre-cardiac markers Mespl, Tbx5, Cxcr4, and Flk-I indicated engagement beyond the original fibroblast lineage (Nelson et al., Stem Cells, 26:1464-1474 (2008) and Nelson et al., Differentiation, 77:248-255 (2009)). Within 12 days, increased expression of canonical cardiac transcription factors, Mef2c (p=0.049; n=3), Gata4 (p=0.049; n=3) and Myocardin (p=0.049; n=3), indicated the capacity for cardiac tissue maturation (Figure 18B). Beyond redirection of somatic cell fate \textit{in vitro}, chimeric embryos were utilized to examine the ability of iPS clones to ensure tissue formation during embryonic development \textit{in utero}. Pre-implantation blastocysts containing lacZ-labeled iPS progenitors were transferred into surrogate uterus, and tracked at early stages of organogenesis. iPS labeled with a constitutively active reporter construct mimicked the stochastic distribution of embryonic stem cells throughout the developing embryo at 9.5 dpc (Figure 18C). Labeled iPS progeny demonstrated robust contribution to the heart field, including cardiac inflow and outflow tracts as well as left and right ventricles of the embryonic heart parenchyma (Figure 18D and 18E). Thereby, qualified iPS clones demonstrated \textit{de novo} organogenesis and patterning of cardiogenic tissue within a developing embryo.

\textit{iPS engraft into infarcted immunocompetent adult hearts.}

In contrast to fibroblasts unable to proliferate even after prolonged incubation, subcutaneous injection of iPS clones within an immunodeficient adult environment demonstrated aggressive growth (Figure 19A). Transplanted cells, initially labeled with retroviral reporter constructs and expanded through multiple passages (>5) \textit{in vitro}, were tracked with \textit{in vivo} imaging using emitted bioluminescence from iPS-derived progeny. Upon permanent occlusion of epicardial coronary vasculature and microsurgical transfer into the ischemic myocardium, iPS remained within injected hearts and produced gradual tumor outgrowth between 2-4 weeks (Figure 19B). Echocardiography confirmed a significant tumor burden, which compromised hemodynamics 4-weeks post-transplant (Figure 19C). Autopsy in immunodeficient recipients (n=6) verified consistent teratoma formation with extension beyond the myocardial wall and tumor infiltration within the post-injured myocardium (Figure 19C). In contrast to tumorigenesis that compromised the safety within immunodeficient environments, subcutaneous transplantation of iPS into immunocompetent hosts demonstrated a persistent absence of tumor growth in all animals (n=6) even at 8 weeks of follow-up (Figure 19D). Furthermore, intramyocardial
transplantation of 200,000 iPS/heart, a dose selected based on tumor-free outcome with embryonic stem cell intervention (Behfar et al., J. Exp. Med., 204:405-420 (2007) and Behfar et al., FASEB J., 16:1558-1566 (2002)), produced stable engraftment without detectable tumor formation (n=6; Figure 19E). According to bioluminescence emitted from labeled progeny, differentiated iPS within ischemic immunocompetent hearts were detectable by 2 weeks post-transplantation without metastatic dissemination after 4 weeks of engraftment (n=6; Figure 19E). In fact, immunostaining of hearts at 4 weeks demonstrated rare iPS progeny positive for SSEA-1 expression within the post-ischemic myocardium (Figure 19F). Immunocompetent recipients thus ensured controlled iPS engraftment (Figure 19G) with tissue integration that did not perturb electrical homeostasis (n=6; Figure 19H). In this way, the immunocompetent adult host provided a permissive environment for differentiation, offering the opportunity to test the therapeutic potential of iPS clones.

*iPS therapy restores myocardial performance lost by ischemic injury.*

Within immunocompetent hosts, recovery of post-ischemic cardiac performance was compared in randomized cohorts transplanted with parental fibroblasts versus derived iPS. Monitored by echocardiography, irreversible occlusion of the epicardial coronary blood flow consistently impaired anterior wall motion, depressed global cardiac function, and halved ejection fraction (EF) from 82±3% before infarction (n=8) to 38±3% within 1-day post-infarction (n=12; Figure 20A). While blinded transplantation with parental fibroblasts demonstrated persistent functional decline with EF dropping to 37±4% at 4 weeks (n=6), iPS intervention improved cardiac contractility to achieve an EF of 56±2% within the first 2-weeks of therapy and 50±5% by 4 weeks (n=6; p=0.002 iPS versus fibroblasts, Figure 20A). Functional benefit in response to iPS was verified by the improved fractional shortening, from 20±1% (median 18%, n=6) at 1-day post-infarction to 31±3% (median 29%, n=6) after 4-weeks, in contrast to a lack of recovery in fibroblast-treated hearts (n=6, p=0.01; Figure 20B). Moreover, the regional septal wall thickness in systole was significantly rebuilt with iPS (1.31±0.11 mm, median 1.20 mm, n=5), but not with fibroblast (0.88±0.06 mm, median 0.90 mm, n=6) treatment (p=0.006; Figure 20C). Impaired cardiac contractility in the injured anterior wall resulted in akinetic regions with paradoxical motion in systole indicative of aneurysms in fibroblast-treated hearts, in contrast to coordinated concentric contractions in response to iPS treatment visualized by long-axis and
short-axis imaging (Figure 2OD and 20E). Thus, compared to non-reparative parental fibroblasts, iPS intervention improved functional performance following acute myocardial infarction.

*iPS therapy halts progression of pathologic remodeling in infarcted hearts.*

Beyond functional deterioration, maladaptive remodeling with detrimental structural changes prognosticates poor outcome following ischemic injury. Here, iPS-based intervention attenuated global left ventricular diastolic diameter (LVDd). Pre-infarction LVDd measured 3.2±0.1 mm (median 3.1 mm), but increased post-infarction to 4.9±0.1 mm (median 4.9 mm) by 4-weeks of fibroblast treatment (n=6) a value significantly higher (p=0.007) than 4.2±0.2 mm (median 4.2 mm) with iPS treatment (n=6; Figure 21A). Furthermore, echocardiography demonstrated regional structural deficits with deleterious wall thinning and chamber dilation in fibroblast-treated hearts (n=6), rescued by iPS intervention (n=6; Figure 21B). Pathologic structural remodeling leads to electrophysiological consequences with prolongation of the QT interval, which increases risk of arrhythmia. Infarction increased QT interval from 28.9±1.4 ms (median 28.1 ms) to 55.9±1.3 ms (median 55.8 ms) in fibroblast-treated hearts (n=6), which was abrogated to 40.8±1.5 ms (median 40.3 ms, n=6) with iPS treatment (p=0.004, Figure 21C). These real-time surrogates for tissue remodeling were confirmed on autopsy on inspection of gross specimen that demonstrated reduced heart size, lack of aneurysmal formation, and absence of severe wall thinning in iPS compared to fibroblast-treated hearts (Figure 21D). Collectively, the favorable remodeling at global, regional, and electrical levels demonstrates overall benefit of iPS therapy in the setting of myocardial infarction.

*Multi-lineage cardiac tissue regeneration following iPS therapy.*

Histological analysis demarcated de-muscularization and extensive scarring within left ventricles distal to coronary ligation in hearts treated with fibroblasts 4 weeks following transplantation (Figure 22A). In contrast, iPS treatment halted structural deterioration of infarcted tissue with anti-fibrotic benefit and remuscularization within the left ventricular free wall (Figure 22A). Surgical dissection and post-mortem histopathological analysis verified absence of tumor infiltration or dysregulated cell expansion following iPS transplantation in the myocardium itself, as well as in the liver, lung and spleen—organs with high metastatic risk.
In post-ischemic myocardium, immunohistochemistry confirmed engraftment of iPS-derived progeny that expressed transgene markers luciferase (not illustrated) or β-galactosidase (Figure 22C-E). Co-localization of transgene expression with cardiac α-actinin was consistent within the damaged territory as documented by microscopy of serial transverse sections (n>10 at 10-20 µm intervals) immediately adjacent to the site of coronary ligation (Figure 22C). Smooth muscle α-actin (Figure 22D) and endothelial CD31 (Figure 22E) were also detectable, albeit at lower frequency, consistent with multi-lineage cardiovascular differentiation of iPS. Thus, in contrast to ineffective parental fibroblasts, targeted delivery of iPS generated de novo cardiovascular tissue in post-ischemic adult myocardium.

**Example 8 - Induced Pluripotent Reprogramming**

**Fibroblasts**

Mouse embryonic fibroblasts (MEFs) were obtained from embryos at 14.5 days post coitum (dpc). Internal organs and the head were removed prior to digestion with 0.25% trypsin-EDTA (Invitrogen, Carlsbad, CA, USA). Digestion was performed three times. Obtained suspension was inactivated with equal volume of EmbryoMax Dulbecco’s modified Eagle’s medium (DMEM; Millipore, Billerica, MA, USA) supplemented with 10% fetal calf serum (FCS), 1% L-glutamine (Invitrogen), and penicillin/streptomycin (Invitrogen). Resulting fibroblasts were plated and grown to confluence in the same medium for two passages. Transduced MEFs were maintained in DMEM (Millipore) supplemented with pyruvate (Lonza, Basel, Switzerland) and L-glutamine (Invitrogen), nonessential amino acids (Mediatech, Herndon, VA, USA), 2-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA), 15% FCS (Invitrogen), and LIF (Millipore).

**HIV packaging plasmid**

The parental packaging plasmid pCMVR8.9129 was used to engineer modifications in the HIV-I capsid region for increased vector transduction efficiency (Ikeda et al., J. Virol., 78(21):1 1816-1 1822 (2004) and Kootstra et al., Proc. Natl. Acad. Sci. USA, 100(3):1298-1303 (2003)). To generate HIV-I packaging constructs carrying the capsid mutations, the Apal, BgIII, and Spel sites in the uncoding region of pCMVR8.9129 were deleted (p8.9Ex). Naturally
occurring capsid amino acid substitutions, which affect the HIV cyclophilin A (Cyp A) dependency, were introduced into the capsid region of the gag gene, resulting in pEx-HV, pEx-QI, and pEx-QV. Vesicular stomatitis virus glycoprotein G (VSV-G)-expressing plasmid, pMD.G (Zufferey et al., Nat. Biotechnol., 15(9):871-875 (1997)) was used for pseudotyping HIV-I vector particles. Infectious HIV vectors were generated by packaging a green fluorescent protein (GFP)-carrying HIV vector genome with the modified constructs and VSV-G, and vector amounts were normalized by the levels of endogenous reverse transcriptase (RT) activity in vector particles. Human, simian, and murine cell lines were infected with various amounts of GFP-expressing vectors, and GFP-positive cell populations were analyzed using fluorescence-activated cell sorting (FACScan, BD Biosciences, Franklin Lake, NJ, USA) and automated quantification (CELL QUEST software; Becton Dickinson, Franklin Lake, NJ, USA). Vector infectivity in each target cell line was determined by infectious units per nanogram RT activity. For MEF transduction, GFP-carrying HIV vectors were generated with a conventional HIV packaging construct (p8.9Ex) or a packaging construct with the V83L, H87Q, and 191V capsid substitutions (pEx-QV). To determine transduction efficiencies, 5 x 10^4 MEFs were infected with increasing amounts of unconcentrated vectors overnight. The number of infected MEFs was determined by GFP-positive cells using FACScan.

**HIV-based transfer vectors**

pSIN-CSGWdlnotl was generated by deleting one of the two Notl sites in the GFP-expressing HIV vector construct, pSIN-SEW (Demaison et al., Hum. Gene Ther., 13(7):803-813 (2002)), which allowed one-step cloning of genes of interest by BamHI and Notl. Transfer vectors were generated with full-length human Oct3/4, Sox2, Klf4, and c-Myc cDNAs (Open Biosystems, Huntsville, AL, USA) amplified using the primer pairs Oct3/4 (5'-ATAGGATCCGTCAGTTTTGAATGCATGGGAGAGCC-3' (SEQ ID NO:1) and 5'-ATAGCGGCCTCACTGGTCCG -3' (SEQ ID NO:2), BamHI-Notl), Sox2 (5'-ATA-GGATCCACCACATGCCGGAGACACCTGCTTTCG GAT-3' (SEQ ID NO:2), BamHI-Notl), Sox2 (5'-ATA-GGATCCACCACATGCCGGAGACACCTGCTTTCG GAT-3' (SEQ ID NO:2), BamHI-Notl), Klf4 (5'-GACGAATTCGGATCCACCATGAGGCAGCCACCTGGCTGCTGCTTAGACG-3' (SEQ ID NO:6), BamHI-XhoI), and c-Myc (5'-GC CTGATCAAGGCTCTCCTTGCAGCTGCTTAGACG-3'
(SEQ ID NO:7) and 5'-ATAGCGGCCGCTTACGCACAAGAGTTCCGTAGCTG-S' (SEQ ID NO:8), Bcll-Notl) cloned into the pSIN-CSGWdlNotl, resulting in pSIN-Oct3/4, pSIN-Sox2, pSIN-Klf4, and pSIN-c-Myc. Human sternness-related factors were driven by a spleen focus-forming virus (SFFV) promoter. HIV vectors were produced by transient transfection of 293T cells using FuGeneβ (Roche, Indianapolis, IN, USA) with a weight ratio of 2:1:1 of vector to packaging to VSV-G plasmids (Ikeda et al, J. Virol, 78(21):11816-1 1822 (2004)). Transfected cells were washed and grown for 48 hours, and supernatants were harvested and passed through a 0.45-μm filter. Vector supernates (10 mL) were concentrated by ultracentrifugation (10^4 g, 2 hours at 4°C), resuspended in 500 μL of serum-free media, aliquoted, and stored at -80°C. For reprogramming, vector titers were determined in MEFs by FACS for GFP-expressing vectors and by immunostaining for sternness factor-encoding vectors.

Western blot

293T/17 cells (CRL-1 1268; ATCC, Manassas, VA, USA) were maintained in DMEM (Invitrogen) supplemented with 10% FCS and antibiotics. Western blots were run on 12% SDS-PAGE gels and transferred to PVDF membranes using the semi-dry method. The membranes were then blocked overnight. Anti-Oct4 (no. 2750S) and anti-Sox2 (no. 2748S) antibodies (Cell Signaling, Boston, MA, USA), anti-c-Myc antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and anti-KLF4 (ab26648-25) antibody (Abeam, Cambridge, MA, USA) were used to verify the expression of human sternness factors in vector-infected cells.

Immunofluorescence

To determine the expression levels, native and transduced MEFs were labeled with anti-Oct4, anti-Sox2, anti-c-Myc, and anti-KLF4 antibodies along with the FITC-conjugated donkey anti-mouse IgG secondary antibody for c-Myc (Jackson Immuno Research, West Grove, PA, USA), and fluorescein isothiocyanate (FITC)-conjugated donkey anti-rabbit IgG for Oct3/4, Sox2, and Klf4 (Jackson Immuno Research). To determine reactivation of pluripotent markers, isolated cell lines were stained with anti-SSEA1 antibody (MAB4301; dilution 1:50; Chemicon International) and anti-Ki67 antibody (1:200; Neomarkers, Fremont, CA, USA) along with secondary antibodies, goat anti-mouse Alexa Fluor 568 (1:250) and goat anti-rabbit Alexa Fluor 488 (1:250; Invitrogen), to visualize markers of undifferentiation. The nuclei were labeled with
4,6’-diamidino-2-phenylindole (DAPI; Invitrogen).

**In vitro differentiation**

Transduced cells were differentiated into three-layer embryoid bodies (EBs) using the hanging-drop method in differentiation media supplemented with 20% FCS without LIF (Behfar et al., *FASEBJ.*, 16(12):1558-1566 (2002); Perez-Terzic et al., *Circ. Res.*, 92(4):444-452 (2003); and Behfar et al., *J. Exp. Med.*, 204(2):405-420 (2007)). Briefly, 25-µL drops from a 25,000 cell/mL suspension were cultured on the lid of a plate for 48 hours. EBs were then flushed and kept in suspension for two days to allow spontaneous differentiation for a total of five days.

**Detection of gastrulation markers**

Expression of pluripotency and gastrulation markers was detected by RT-PCR. Total RNA was extracted with a combination of gDNA Eliminator and RNeasy columns (Qiagen, Valencia, CA, USA). cDNA was prepared from total RNA samples using Superscript III First Strand (Invitrogen). Mouse GAPDH (4352932E; Applied Biosystems, Foster City, CA, USA) was used as control. Analyzed genes included Fgf4 (Mm00438917_ml), Gsc (Mm00650681_gl), Sox17 (Mm00488363_ml), Pou5fi (Mm00658129_gH), Zicl (Mm01239008_mH), and Sox2 (Mm00488369_sl; Applied Biosystems).

**Teratoma formation**

Native and transduced fibroblasts were injected subcutaneously into the flank skin of anesthetized athymic nude mice at a dose of 500,000/50 µL medium. Tumor growth was monitored daily until the tissue was harvested. Tumors were processed by rapid freezing and cut by cryosections at 7-µm thickness to be stained with standard hematoxylin/eosin procedures.

**Chimeric blastocyst formation**

**In vivo** contribution of transduced cells to embryonic development was assessed through diploid aggregation with preimplantation morula. CDI females at 3 weeks of age were superovulated using intraperitoneal injection of pregnant mare serum gonadotropin and human chorionic gonadotrophin, followed by pairing with adult CDI males for timed pregnancy. Embryos at 2.5 days dpc were harvested, washed in EmbryoMax M2 medium (Millipore), and
denuded from zona pelucida to produce morula competent for stem cell integration. After washing through M2 and EmbryoMax KSOM (Millipore) solutions, the embryos were plated as pairs in microweils to facilitate aggregation. Engineered stem cells were labeled for in vivo imaging by infection with a GFP-carrying HIV vector generated with a conventional HIV packaging construct (p8.9Ex). Labeled cells cultured for at least two passages after thawing were partially digested using trypsin 0.25%-EDTA (Invitrogen) and preplated for 45 minutes to allow attachment of feeders to the plate. Floating clumps (8-15 cells) were individually picked and washed in M2 medium and KSOM medium before being placed adjacent to the pair of embryos in microweils. The aggregation complex was incubated in a table-top incubator (Thermoﬁsher, Waltham, MA, USA) with continuous flow of a humidified gas mixture (5% CO₂/5% O₂/90% N₂) for 24 hours until cavitation of the blastocysts (Nelson et al., Phil. Trans. R. Soc. B., 364(15 14):269-276 (2008)).

In utero organogenesis

CDI females in estrus were identified and paired with vasectomized studs two days prior to aggregation to produce pseudopregnant mice. Surrogate mothers were anesthetized (2-3% inhaled isoﬂurane), their uteruses were dissected through a minimal flank incision, and blastocyst-stage chimeric aggregates containing transduced cells were transferred into the distal portion of the uterus. Pregnancy was supported by pseudopregnant females until 9.5 dpc when embryos were harvested and analyzed for transduced cell distribution using an LSM 510 laser scanning confocal microscope (Carl Zeiss, Oberkochen, Germany).

Results

Engineered HIV vector packaging constructs for improved transduction efficiency across species

Efficient HIV infection requires Cyp A in target human cells, with sequence variations in the Cyp A-binding loop of the capsid protein affecting viral infectivity. Capsid mutations were used here to improve infectivity of HIV-based vectors across species in order to test human sternness-related factors in nonhuman cell types (Figure 23A). By generating GFP-expressing HIV vectors containing speciﬁc mutations in the Cyp A-binding loop region, the efficiency of infectivity was quantiﬁed in multiple cell lines. When the vector particle numbers were adjusted to the virion reverse transcriptase activities, the engineered packaging constructs pEx-QV and pEx-QI exhibited improved infectivity when screened in simian FrhK4 or CV1 cells as well as in
murine P815 or EL4 cells compared with the parental p8.9-Ex vector without affecting vector infectivity in human cells (Figure 23A). The absolute infectious vector yields were 2- to 3-fold higher with pEx-QV over p8.9-Ex or modified pEx-QI. Furthermore, the pEx-QV packaged HIV vector transduced MEFs more efficiently than the parental p8.9-Ex (Figure 23B). The validated packaging construct pEx-QV was therefore selected to deliver sternness-related factors.

Efficient expression of human sternness factors in nonhuman recipients

Human sequences were used to generate reprogramming vector sets to be tested in evolutionary distant somatic cell types. Gene sequences demonstrated a high degree of conservation, with the lowest percentage of homologies noted between Oct3/4 orthologs at 84%. This degree of homology is similar to the sequence for LIF, which does not conserve maintenance of pluripotency in human (Daheron et al., Stem Cells., 22(5):770-778 (2004)) as required for mouse stem cells (Figure 24A). Human cDNAs for sternness-related factors were amplified by PCR, cloned into self-inactivating vector plasmid, and packaged into the selected pEx-QV HIV packaging construct to produce expression vectors encoding human OCT-3/4, SOX2, KLF4, and c-MYC (Figure 24B). Proper expression was verified in human 293T cells with predicted molecular weight transgene products detected by immunoblotting with OCT-3/4, SOX2, KLF4, and c-MYC antibodies (Figure 24C). Robust transgene expression of the four human sternness-related factors was also detected in >90% of MEFs (Figure 24D). Thus, the pEx-QV HIV-based lentiviral platform demonstrated cross-species tropism and consistently delivered interspecies transduction of human pluripotent genes.

Virus-transduced human sternness factors reprogram mouse fibroblasts

To determine whether human sternness-related factors can reprogram mouse somatic cells, ectopic gene expression was achieved in MEFs. A GFP-expressing vector was infected into MEFs at a multiplicity of infection (MOI) of 20 as the control to determine any spontaneous cellular changes (Figure 25A). Human pluripotent genes for OCT3/4, SOX2, c-MYC, and KLF4 were transduced together in parallel experiments at an MOI of 5 each (Figure 25B). Two days post infection, transduced cells were passaged and monitored for the formation of embryonic stem cell-like colonies, according to morphology, consisting of compact cell clusters. In contrast to monomorphic single-cell layered fibroblasts in GFP control groups, MEFs treated with the
combination of four human factors produced numerous colonies after 7 days (Figure 25B, inserts) and were of sufficient size to isolate individual clones after 10 days. Compared with native MEFs (Figure 25C), clonal expansion of isolated colonies produced rapidly dividing cell lines without contact inhibition and with maintained embryonic stem cell morphology through a minimum of 10 passages (Figure 25D). Transduced MEFs demonstrated ongoing cell divisions according to Ki67 expression (Figure 25E and 25F). In contrast to parental fibroblasts that lack pluripotent markers, transduced cells uniquely expressed the early stage-specific mouse embryonic antigen (SSEA-I; Solter et al, Proc. Natl. Acad. Sci. USA, 75(1):5565-5569 (1978)) as a characteristic of sternness (Figure 25G and 25H). Thus, the engineered platform based on human sternness factors induced efficient metamorphosis of murine fibroblasts into clonal populations, recapitulating growth kinetics and a cellular expression profile consistent with an embryonic stem cell phenotype.

In vitro differentiated transduced fibroblasts display a genetic pedigree characteristic of gastrulating tissues

To identify the diversity of lineage differentiation, gene expression analysis was performed according to protocols established for embryonic stem cells (Behfar et al, J. Exp. Med, 204(2):405-420 (2007); Faustino et al, Genome Biol, 9:R6 (2008); and Nelson et al, Stem Cells., 26(6):1464-1473 (2008)). Parental MEFs provided the baseline for gene expression comparison. Following viral transduction, derived progenitors were differentiated in three-dimensional cultures to allow spontaneous germ layer formation. Sequential differentiation produced EBs at day 5 with dense compaction of cells within a sphere of tissue (Figure 26A). Gene expression analysis demonstrated a downregulation of pluripotent markers Oct4, Sox2, and Fgf4 by day 5 of differentiation (Figure 26B). Concomitantly, transduced progenitors gained the expression of mesoderm lineage marker Gsc, endoderm marker Sox17, and ectoderm marker Zicl after 5 days of differentiation (Figure 26C). Thus, early lineage marker induction fulfilled in vitro criteria for xenogenic nuclear reprogramming with human sternness-related genes.

In vivo lineage differentiation of transduced fibroblasts

Pluripotent cells form spontaneous teratomas following transplantation into immunodeficient mice, an established assay to demonstrate multilineage developmental capacity.
Here, immunodeficient mice were subcutaneously injected with native MEFs or transduced counterparts. Only transduced cells gave rise to tumors, following injection at a dose of 500,000 cells, that enlarged to 1 cm in diameter within 4 weeks, in contrast to undetectable growth for native MEFs injected on the contralateral side (Figure 27A). Tumors derived from transduced MEFs were encapsulated and demonstrated a heterogenous appearance consisting of vascular networks and nonvascularized tissues on gross inspection (Figure 27B). Tissue histology revealed cellular architecture consisting of mesoderm lineages indicated by muscle (Figure 27C), ectoderm lineages denoted by keratinized tissues (Figure 27D), endoderm lineages composed of specialized epithelium (Figure 27E), and persistence of poorly differentiated cytotypes (Figure 27F). Together, these data documented the multiple tissues derived from in vivo differentiation and spontaneous formation of complex cytoarchitecture derived from mouse fibroblasts reprogrammed by human sternness-related factors.

**Contribution of transduced progeny into ex utero blastocysts**

A hallmark characteristic of pluripotent stem cells is the ability to incorporate into 8-cell embryos and form morula capable of developing into chimera blastocysts (Wood et al., *Nature*, 365(6441):87-89 (1993)). Primitive stem cell populations engraft within host 8-cell embryos to form mosaic blastocysts, but are universally excluded upon the loss of functional pluripotency Stewart, *J. Embryol. Exp. Morphol.*, 58:289-302 (1980) and Fujii and Martin, *Dev. Biol.*, 74(1):239-244 (1980) despite persistent expression of stem cell markers (Nagy et al., *Development*, 110(3):815-821 (1990)). In order to determine the ability of reprogrammed MEFs to incorporate into early-stage morula, the cells were lentivirally labeled with GFP, expanded in vitro, and prepared for diploid aggregation with unlabeled embryos (Figure 28A and 28B). GFP-tagged transduced progeny retained the ability to engraft into 8-cell embryos (Figure 28C) and contribute to chimeric embryos capable of spontaneous formation of blastocysts with appropriate cavitating morphology (Figure 28D). Diploid aggregation thus provided an efficient ex utero methodology to characterize functional properties of transduced MEFs within a permissive embryonic niche. Specifically, reprogrammed progenitors containing human sternness-related factors revealed the primordial characteristic of pluripotency in embryos with morula integration and blastocyst development, expanding the stringency of pluripotency functional criteria.
High-fidelity organogenesis from transduced progeny

Beyond ex vivo characterization, chimeric embryos establish in situ competency of transduced progeny during natural embryogenesis. Pluripotent stem cells contain the capacity to give rise to all lineages of the developing embryo upon blastocyst integration in a stochastic pattern, depending on the location of blastomere integration during early stage of preimplantation development (Nagy et al., Development, 110(3):815-821 (1990)). Mosaic embryos produced by diploid aggregation using GFP-labeled progenitors were transferred to the uterus of a pseudopregnant surrogate for in utero implantation and differentiation. Chimeric embryos were harvested at 9.5 dpc and analyzed for engraftment and differentiation of nonnative progeny. Embryos that demonstrated normal morphology and appropriate developmental stages of organogenesis were visualized for GFP expression. Transduced progenitors were identified throughout the embryo in multiple developing organs that included central nervous tissue (Figure 29A and 29B), pharyngeal arch (Figure 29C), the heart (Figure 29D), emerging limb buds (Figure 29E), and somites (Figure 29F). Thus, stochastic integration and widespread tissue contribution of reprogrammed cells demonstrated unrestricted differentiation potential and competitive fitness equal to that of native blastomeres, achieving a rigorous criterion to define pluripotency with competent in utero orchestrated organogenesis.

Example 9 - Generation of iPS cells from a hemophiliac mouse through human factor-mediated interspecies reprogramming

Induced pluripotent stem (iPS) cells represent the newest platform for gene and cell therapy. HIV-I vectors carrying human pluripotency genes, OCT3/4, SOX2, KLF4 and c-MYC, were used to reprogram primary human fibroblasts and keratinocytes into iPS cells. The resulting iPS cell clones were positive for human embryonic stem (ES) cell markers (alkaline phosphatase, SSEA4, TRA-1-60, and TRA-1-81) and expressed other pluripotency-related genes, such as hTERT, Nanog, and GDF3. Use of human feeder cells and serum-free media allowed for the generation of xeno-free human iPS cells. To determine whether human sternness-related factors can reprogram mouse somatic cells, murine fibroblast cells were infected with these HIV-I vectors. Despite the variations in primary amino acid sequences between human and mouse factors, expression of human OCT3/4, SOX2, KLF4, and c-MYC efficiently reprogrammed mouse cells into iPS cells. The resulting iPS cells expressed stem cell
markers, differentiated in vitro into all three germ layers according to gastrulation gene expression profiles, and formed in vivo teratoma with multilineage potential. Moreover, the iPS cells were incorporated into a mouse morula to produce blastomeres capable of developing into chimeric embryos with competent organogenesis. The interspecies nuclear reprogramming suggests the evolutionary conserved process of induced pluripotency. This system was applied to generate iPS cells from a factor VIII (FVIII) knockout mouse for hemophilia A gene and cell therapy applications. The tail fibroblast-derived iPS cells exhibited ES-like phenotypes and could be differentiated into beating cardiomyocytes. Since liver sinusoidal endothelial cells produce FVIII in vivo, different in vitro endothelial differentiation protocols using wildtype and FVIII knockout iPS cells can be examined.

Example 10 - iPS Programmed Without c-MYC Yield Proficient Cardiogenesis for Functional Heart Chimerism

**Fibroblast transduction**

Mouse embryonic fibroblasts (MEF), plated in Dulbecco's modified Eagle's medium with 10% FCS, 1% L-glutamine and penicillin/streptomycin (Invitrogen) at 10^5 per 24-well plate, were infected for 12 hours with full-length human OCT3/4, SOX2 and KLF4 cDNAs (Open Biosystems) using a lentivirus system. The rationale for using human genes for reprogramming was to determine whether human cDNA is phylogenetically conserved to produce iPS with cardiogenic potential. MEF were maintained in Dulbecco's modified Eagle's medium supplemented with pyruvate (Lonza) and L-glutamine, non-essential amino acids (Mediatech), 2-mercaptoethanol (Sigma-Aldrich), 15% FCS and LIF (Millipore). Within three weeks, iPS clones were isolated and labeled with LacZ and luciferase using pLenti6/UbC/V5-GW/LacZ (Invitrogen) and a pSIN-Luc luciferase-expressing vector. Vector integration was PCR confirmed from genomic DNA (Sigma-Aldrich, XNAT2) using primers for OCT4-R AGC-GTCGCGCGGGCACTAGCCC (SEQ ID NO:9), KLF4-R CGCAAGCGCCACCGTCCG (SEQ ID NO: 10), SOX2-R AGCCTCGATGAGCGCGCCGC (SEQ ID NO: 11), and SFFVprom-F CTCACTCGGGGCGCCGCTC (SEQ ID NO: 12). PCR products were resolved on 1% agarose gel electrophoresis.

*Cell sorting and electron microscopy*
LacZ labeled clonal populations were trypsinized, incubated with Fluorescein di[β-D-galactopyranoside] (Sigma-Aldrich, F2756), and sorted using a FACS Aria SE flow cytometer (BD Biosciences). On fixation with 1% glutaraldehyde and 4% formaldehyde in 0.1 M phosphate buffered saline (pH 7.2), cells were examined on a Hitachi 4700 field emission scanning microscope. For ultrastructural evaluation, fixed cells were ultramicrotome cut, and stained with lead citrate prior to examination on a JEOL 1200 EXII electron microscope.

**Immunostaining and confocal microscopy**

Cells were stained with anti-SSEA1 antibody (MAB4301; dilution 1:50; Millipore) along with secondary goat anti-mouse IgG Alexa Fluor 568 (Sigma A1103 1; 1:250) or alkaline phosphatase detection kit (Millipore, SCR004). Immunostaining of derivatives was performed using monoclonal mouse anti-alpha-actinin (Sigma A781 1, 1:200), rabbit anti-connexin 43 (Zymed 483000, 1:200), rabbit anti-Mef2c (proteintech 10056-1-AP, 1:50), monoclonal mouse anti-myosin light chain 2a (MLC2a, Synaptic Systems 31101 1, 1:250), and anti-cardiac troponin I (Abeam 47003, 1:500). Secondary antibodies (Invitrogen) were used at a 1:250 dilution (i.e., goat anti-mouse IgG Alexa Fluor 568, donkey anti-mouse IgG Alexa Fluor 488, and goat anti-rabbit IgG Alexa Fluor 488). Nuclei were labeled with 4,6-diamidino-2-phenylindole (DAPI; Invitrogen). Images were taken using laser confocal microscopy (Zeiss LSM 510 Axiovert). For LacZ staining, samples were fixed with 0.25% gluteraldehyde for 15 minutes at room temperature prior to β-galactosidase staining.

**In vivo and in vitro differentiation**

Transduced fibroblasts were injected subcutaneously into the flank skin of anesthetized athymic nude mice or immunocompetent C57BL/6 strain of mice at 500,000/50 µL medium. Local growth was monitored daily until tissue was harvested and processed by rapid freezing and cryosectioned for hematoxylin/eosin procedures. Separately, iPS were differentiated into three-layer embryoid bodies (EB) using the hanging-drop method. Digital serial images were analyzed with Metamorph (Visitron Universal Imaging).

**Gene expression**

Expression of pluripotent, gastrulation, and cardiac markers was detected by RT-PCR.
Mouse Gapdh (4352932E; Applied Biosystems) was used as control. Analyzed genes included Sox2 (Mm00488369_sl), Oct4 (Mm00658129_gH), Fgf4 (Mm00438917_ml), Gsc (Mm00650681_gl), Sox17 (Mm00488363_ml), Mesp2 (Mm00655937_ml), Tbx5 (Mm00803521_ml), Nkx2.5 (Mm00657783_ml), and Mef2c (Mm01340839_ml; Applied Biosystems).

**Patch clamp and calcium imaging**

Derived cardiomyocytes, enriched by dual interface Percoll gradient (Invitrogen) (Hodgson et al, *Am. J. Physiol. Heart Circ. Physiol.*, 287:H471-479 (2004)), were plated on laminin coated coverglass for >24 hours. Membrane electrical activity was determined by patch-clamp recording in the whole cell configuration using current- or voltage-clamp mode (Axopatch 1C, Axon Instruments). Action potential profiles and voltage-current relations were acquired and analyzed with the Bioquest software. Cells were superfused with Tyrode solution containing (in mM) 137 NaCl, 5.4 KCl, 2 CaCl₂, 1 MgCl₂, 10 HEPES, and 10 glucose (with pH adjusted to 7.3 with NaOH) or calcium-free Tyrode in which CaCl₂ was replaced by EGTA 5 mM. Patch pipettes (5-10 MΩ) containing (in mM) 140 KCl, 1 MgCl₂, 10 HEPES, 5 EGTA, and supplemented with 5 mM ATP (with pH adjusted to 7.3 with KOH) were used for electrophysiological measurements performed at 34±1°C set by a Peltier thermocouple temperature controller. To assess intracellular Ca²⁺ dynamics, cells were loaded with the Ca²⁺-fluorescent probe Fluo 4-AM (Invitrogen), imaged with a Zeiss LSM live 5 laser confocal microscope, and analyzed using LSM software.

**Chimeric blastocyst formation and in utero organogenesis**

CD1 embryos were harvested at 2.5 days post coitum (dpc) and plated as pairs in microwells for diploid aggregation. LacZ-labelled cells cultured for at least two passages after thawing were partially digested using trypsin 0.25%-EDTA and pre-plated for 45 minutes to allow attachment of feeders. Floating clumps (8-15 cells) were co-incubated with embryo pairs in microwells. The aggregation complex was incubated for 24 hours until cavitation of blastocysts. Surrogate mothers were anesthetized (2-3% inhaled isoflurane), uterus dissected through a minimal flank incision, and blastocyst-stage chimeric aggregates transferred into the uterus. Pseudopregnant females supported pregnancy until days 8.0-9.5 dpc, when embryos
were harvested and analyzed for LacZ-labelled progenitors using a ProgRes C3 camera-equipped Zeiss stereo Discovery V20 microscope. Embryos were fixed with 0.25% gluteraldehyde for 15 minutes at room temperature prior to β-galactosidase staining.

**Molecular imaging**

Luciferase-transfected iPS were cultured for multiple passages including a freeze/thaw cycle prior to expansion and transplantation into recipients. Cells were tracked with the IVIS 200 Bioluminescence Imaging System (Xenogen) following intra-peritoneal injection of 150 mg/kg D-luciferin (Xenogen), and signals analyzed with the Living Image Software (Xenogen).

**Electrocardiography and echocardiography**

In age-matched control and iPS-chimera mice under anesthesia (1.5% isoflurane), heart rate and rhythm were measured using 4-limb lead electrocardiography (MP150, Biopac). Cardiac structure and left ventricular contractility were quantified by trans-thoracic echocardiography using a 30 MHz MS400 transducer (Vevo2100, Visual Sonics).

**Statistics**

Data were presented as mean±SEM. Student's t test was used to evaluate significance of PCR data. Wilcoxon test was used to evaluate physiological parameters between chimeric and non-chimeric cohorts. A p value <0.05 was predetermined.

**Results**

*Phylogenetically conserved nuclear reprogramming with human sternness factor independent of c-MYC*

MEFs grown in monolayers demonstrated contact inhibition upon culture confluency. Elongated flat cells typical of fibroblasts provided a homogenous population of starting somatic tissue (Figure 30A). Upon cross-species transduction with three human sternness-related factors, SOX2, OCT4, and KLF4 vector-derived transgenes were stably integrated in engineered progeny, absent from the untransduced parental source (Figure 30A). Scanning electron microscopy documented structural metamorphosis, revealing isolated colonies that exhibited a condensed morphology in contrast to the flat untransduced neighboring fibroblasts (Figure 30B,
Transmission electron microscopy imaged a reduced cytosol-to-nuclear ratio in transduced progeny, indicating acquisition of primitive cell phenotype (Figure 30B, right side). Tightly packed colonies, which represent clonal clusters of reprogrammed cells, robustly expressed markers of pluripotency, alkaline phosphatase (AP; left side) and SSEA-I (right side), negligible in parental fibroblasts (Figure 30C). To validate acquired pluripotency in vivo, cells transduced with three human sternness factors (3F-iPS) were injected subcutaneously into immunodeficient mice. Within weeks following delivery of 500,000 3F-iPS, three germ layers were detected on histology, including glandular epithelium (endoderm), keratinized epidermal ectoderm (ectoderm), and mesenchymal derived connective tissue (mesoderm; Figure 31A). Molecular analysis identified cardiac tissue that demonstrated sarcomeric striations (Figure 31B, left), and typical markers such as alpha-actinin (Figure 31B, middle), cardiac troponin I and sarcolemmal connexin 43 (Figure 31B, right). Thus, human transcription factors SOX2, OCT4, and KLF4, in the absence of c-MYC, induced phylogenetic nuclear reprogramming from murine fibroblasts to achieve functional pluripotency across species.

Threefactor iPS-derived embryoid bodies unmask reproducible cardiogenic potential

Distinct 3F-iPS clones consistently yielded clusters of undifferentiated cells capable of generating embryoid spheroids at day 5 following a hanging-drop protocol, and differentiated in three-dimensional cultures throughout a 12-day period (Figure 32A). iPS progeny were sampled sequentially starting at day 0 monolayers (Figure 32A, top), day 5 floating embryoid spheres (Figure 32A, middle), and day 12 plated embryoid bodies (Figure 32A, bottom). Gene expression analysis from two independent clones, sampled throughout the continuum of differentiation, demonstrated immediate, sustained, and reproducible downregulation of pluripotent markers Oct4, Sox2, and Fgf4 (Figure 32B; p<0.05). Recapitulating gastrulation in the embryo, induction of mesoderm (Goosecoid, Gsc) and endoderm (Sox17) peaked by day 5 in iPS-derived embryoid bodies, giving rise to the pre-cardiac mesoderm identified by Mesp2 expression (Figure 32C; p<0.05). Cardiac differentiation was further indicated by a 20-30 fold upregulation in cardiac transcription factors Tbx5, Nkx2.5, and Mef2c by day 12, compared to undifferentiated day 0 iPS (Figure 32D; p<0.05). Thus, the pattern of gene expression in 3F-iPS, verified across all tested clones, revealed exchange of genes with pluripotent potential for the acquired proficiency of lineage specification, ensuring reproducible cardiogenic outcome.
**Functional cardiogenesis derived from 3F-iPS**

iPS differentiating within embryoid bodies (EB) were examined daily to quantify the percentage of EB that acquired cardiac phenotype tracked by spontaneous beating activity. Independent clones derived by three-factor reprogramming revealed consistent progression of beating activity as early as seven days following progeny differentiation (Figure 33A) that corresponded to expression of cardiac contractile proteins (Figure 33A, inset). From -10% of contracting EB within independent clones starting two days after plating EB at day 5, the percentage of beating areas progressively increased through day 11 with 54-72% of all colonies containing at least one area of spontaneous contractions (Figure 33A). Notably, EB that demonstrated multiple beating areas (Figure 33B top, rectangles) developed synchronized contractile rhythm underlying coordinated electrical activity that propagated through the syncytium of nascent cardiac tissue (Figure 33B bottom). Isolation of cardiomyocytes from beating EB was achieved using a selective density gradient. Structural changes consistent with cardiac differentiation were observed at day 12 as 3F-iPS progeny developed rod-shaped morphology (Figure 33C, top), a mature myofibrillar organization (Figure 33C, middle), and gap junctions that bridged adjacent progeny (Figure 33C, bottom). Similarly, iPS-derived cells demonstrated presence of the cardiac transcription factor Mef2c, contractile protein alpha actin, and gap junction-protein connexin 43 (Figure 33D). Moreover, spontaneous action potential activity was recorded in isolated cells under whole cell current-clamp mode (Figure 33E). Under voltage-clamp, depolarization of 3F-iPS progeny by membrane potentials imposed ramp pulses from -100 to +60 mV revealed prominent inward and outward current components, not present in non-excitable parental fibroblasts (Figure 34A). The inward current component was eliminated in the absence of external Ca\(^{2+}\) (Figure 34B). Furthermore, removal of Ca\(^{2+}\) reversibly abolished action potential activity in 3F-iPS derived cardiac cells (Figure 34C).

Loaded with the calcium selective Fluro-4AM probe, 3F-iPS derived cardiomyocytes demonstrated rhythmic transients consistent with calcium dynamics in diastole versus systole (Figure 34D), in synchrony with force-generating mechanical contractions (Figure 34E). These data indicated reproducible derivation of 3F-iPS progeny that progressively acquired authentic cardiogenic machinery required for excitation-contraction coupling, and generation of functional cardiomyocytes.
3F-iPS chimerism contributes to de novo heart tissue formation in the embryo and sustains cardiac function in the adult heart

Non-coerced diploid aggregation at the morula stage allows competent pluripotent stem cells to assimilate within a developing embryo and contribute to chimeric organogenesis. 3F-iPS labeled with LacZ and luciferase expression cassettes were clonally expanded and allowed aggregation with two, 8-cell morula embryos (Figure 35A and 35B). The process of diploid aggregation, that engages equivalent progenitors into a chimeric blastocyst, exploited the ability of 3F-iPS to integrate into host embryos and function as a blastomere, demonstrated by mosaic distribution of positive lacZ-expressing iPS progeny (Figure 35C and 35D). iPS-derived tissue populated the embryo (n=7) during development and contributed to all stages of cardiogenesis from primitive heart fields to looped heart tubes corresponding to 8.0 to 9.5 dpc, respectively (Figures 35E-6G). By 9.5 dpc when the heart tube has fully looped to form distinct inflow and outflow tracts, iPS progeny was detected throughout nascent heart parenchyma (Figures 35G, inset). Live born 3F-iPS demonstrated iPS contribution and engraftment throughout adult tissues with dark coat color visible on the white background (n=5; Figure 35H). Transgenic luciferase expression emanating from labeled iPS progeny upon in vivo imaging ranged from undetectable levels to a high degree of achieved chimerism. Chimeric offspring (n=5), including those with the highest contribution of iPS progeny (Figure 35I), demonstrated tumor-free assimilation throughout the three months of follow-up. This profile was independently verified by lack of tumor formation during 7.5 months of prospective follow-up upon subcutaneous injection of 500,000 3F-iPS into the flank of immunocompetent hosts (n=6). In line with non-disruptive integration, iPS chimera (n=5) exhibited vital signs, including average body weight, core temperature, heart and respiratory rates, that were indistinguishable from non-chimera counterparts (n=5; Table 3). Based on continuous electrocardiography, the chimeric cohort was devoid of ectopy, arrhythmias, or conduction blocks (Figure 35J). Comprehensive echocardiography analysis further demonstrated consistent cardiac structure between 3F-iPS chimera and non-chimera cohorts with similar measured values for aortic, pulmonary, and right outflow tract diameters, along with equivalent left atrium and left ventricular volumes (Table 3). Synchronized four-chamber function throughout systolic and diastolic cardiac cycles, indicating functional integration of 3F-iPS progeny into the adult organ, was also equivalent to non-chimera
counterparts (n=5, Figure 35K and Table 3). Left ventricular functional performance of all 3F-iPS chimeras was essentially identical, according to measured fractional shortening and ejection fraction, compared to age and sex-matched normal controls (Table 3). Together, this evidence indicates a high proficiency for 3F-iPS progeny to contribute to normal heart formation, and sustain chimeric tissue without disruption to myocardial structure or function throughout prenatal to postnatal development.

Table 3. Cardiovascular comparison between non-chimera and 3F-iPS chimeric cohorts.

<table>
<thead>
<tr>
<th>Cohort, n</th>
<th>Non-chimera</th>
<th>Chimera</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vital signs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight, g</td>
<td>33.8±1.0</td>
<td>36.2±2.1</td>
<td>0.25</td>
</tr>
<tr>
<td>Body core temperature, °C</td>
<td>35.2±0.8</td>
<td>35.8±0.6</td>
<td>0.46</td>
</tr>
<tr>
<td>Respiration rate, /min</td>
<td>117±3</td>
<td>112±2</td>
<td>0.34</td>
</tr>
<tr>
<td>Heart rate, beats/min</td>
<td>469±1.0</td>
<td>455±9</td>
<td>0.29</td>
</tr>
<tr>
<td>Cardiovascular structure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascending aorta, mm</td>
<td>1.68±1.09</td>
<td>1.58±0.04</td>
<td>0.35</td>
</tr>
<tr>
<td>Main pulmonary artery, mm</td>
<td>1.80±0.14</td>
<td>1.81±0.14</td>
<td>0.75</td>
</tr>
<tr>
<td>Right ventricular outflow tract, mm</td>
<td>1.32±0.18</td>
<td>1.31±0.19</td>
<td>0.99</td>
</tr>
<tr>
<td>Left atrium, mm</td>
<td>1.79±0.13</td>
<td>2.04±0.19</td>
<td>0.35</td>
</tr>
<tr>
<td>LVDd/BW, mm/g</td>
<td>0.106±0.01</td>
<td>0.113±0.01</td>
<td>0.60</td>
</tr>
<tr>
<td>Left ventricular end-diastolic volume, µL</td>
<td>59.2±3.3</td>
<td>61.5±6.3</td>
<td>0.92</td>
</tr>
<tr>
<td>Left wall thickness (septum plus posterior wall), mm</td>
<td>1.43±0.05</td>
<td>1.56±0.08</td>
<td>0.25</td>
</tr>
<tr>
<td>Left ventricle/body weight, mg/g</td>
<td>2.52±0.24</td>
<td>3.22±0.30</td>
<td>0.12</td>
</tr>
<tr>
<td>Cardiac function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fractional shortening, %</td>
<td>46.6±2.8</td>
<td>45.4±3.1</td>
<td>0.75</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>61.7±3.9</td>
<td>63.6±1.8</td>
<td>0.92</td>
</tr>
</tbody>
</table>

LVDd, left ventricular diastolic diameter. BW, body weight.

In one experiment, the beating activity observed in iPS reprogrammed with four factors (SOX2, OCT4, KLF4, and cMYC; n=2) was compared to the beating activity observed in iPS reprogrammed with three factors (SOX2, OCT4, and KLF4; n=2) and in an embryonic stem cell line (ESC) during day 7 to 11 of differentiation. The three factor iPS exhibited a similar trend as reference ESC (Figure 36). No beating activity was observed in four factor iPS during the differentiation period.

In summary, these results demonstrate that transgenic expression of three human sternness factors, SOX2, OCT4, and KLF4, can reset fibroblasts (e.g., murine fibroblasts) to the pluripotent ground state. Transduction without c-MYC reversed cellular ultrastructure into a
primitive archetype and induced stem cell markers generating three-germ layers, all qualifiers of acquired pluripotency. Three-factor induced iPS (3F-iPS) clones reproducibly demonstrated cardiac differentiation properties characterized by vigorous beating activity of embryoid bodies and robust expression of cardiac Mef2c, alpha-actinin, connexin43, MLC2a, and troponin I. *In vitro* isolated iPS-derived cardiomyocytes demonstrated functional excitation-contraction coupling. Chimerism with 3F-iPS derived by morula-stage diploid aggregation was sustained during prenatal heart organogenesis, and contributed *in vivo* to normal cardiac structure and overall performance in adult tumor-free offspring. Thus, 3F-iPS bioengineered without c-MYC achieve highest stringency criteria for bona fide cardiogenesis enabling reprogrammed fibroblasts to yield *de novo* heart tissue compatible with native counterpart throughout embryologic development and into adulthood.

**OTHER EMBODIMENTS**

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
WHAT IS CLAIMED IS:

1. An induced pluripotent stem cell comprising nucleic acid encoding one or more polypeptides selected from the group consisting of a human Oct3/4 polypeptide, a human Sox family polypeptide, a human KIf family polypeptide, a human Myc family polypeptide, a human Nanog polypeptide, and a human Lin28 polypeptide, wherein the origin of said induced pluripotent stem cell is a non-human species.

2. The induced pluripotent stem cell of claim 1, wherein said non-human species is selected from the group consisting of mouse, rat, hamster, guinea pig, rabbit, cat, dog, pig, sheep, goat, cow, horse, and monkey species.

3. The induced pluripotent stem cell of claim 1, wherein said induced pluripotent stem cell was induced from a somatic cell.

4. The induced pluripotent stem cell of claim 3, wherein said somatic cell is selected from the group consisting of skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells.

5. The induced pluripotent stem cell of claim 1, wherein said human Sox family polypeptide is a Sox2 polypeptide.

6. The induced pluripotent stem cell of claim 1, wherein said human KIf family polypeptide is a Klf4 polypeptide.

7. The induced pluripotent stem cell of claim 1, wherein said human Myc family polypeptide is a c-Myc polypeptide.

8. The induced pluripotent stem cell of claim 1, wherein said induced pluripotent stem cell comprising nucleic acid encoding said human Oct3/4 polypeptide, said human Sox2 polypeptide, said human Klf4 polypeptide, and said human c-Myc polypeptide.
9. An induced pluripotent stem cell comprising nucleic acid encoding one or more polypeptides selected from the group consisting of a non-human Oct3/4 polypeptide, a non-human Sox family polypeptide, a non-human KIf family polypeptide, a non-human Myc family polypeptide, a non-human Nanog polypeptide, and a non-human Lin28 polypeptide, wherein the origin of said induced pluripotent stem cell is human.

10. The induced pluripotent stem cell of claim 9, wherein said one or more polypeptides are of mouse, rat, hamster, guinea pig, rabbit, cat, dog, pig, sheep, goat, cow, horse or monkey origin.

11. The induced pluripotent stem cell of claim 9, wherein said induced pluripotent stem cell was induced from a human somatic cell.

12. The induced pluripotent stem cell of claim 11, wherein said human somatic cell is selected from the group consisting skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells.

13. The induced pluripotent stem cell of claim 9, wherein said non-human Sox family polypeptide is a Sox2 polypeptide.

14. The induced pluripotent stem cell of claim 9, wherein said non-human KIf family polypeptide is a Klf4 polypeptide.

15. The induced pluripotent stem cell of claim 9, wherein said non-human Myc family polypeptide is a c-Myc polypeptide.

16. The induced pluripotent stem cell of claim 9, wherein said induced pluripotent stem cell comprising nucleic acid encoding said non-human Oct3/4 polypeptide, a non-human Sox2 polypeptide, a non-human Klf4 polypeptide, and a non-human c-Myc polypeptide.
17. An induced pluripotent stem cell, wherein said induced pluripotent stem cell was obtained using nucleic acid encoding one or more polypeptides selected from the group consisting of a human Oct3/4 polypeptide, a human Sox family polypeptide, a human Klf family polypeptide, a human Myc family polypeptide, a human Nanog polypeptide, and a human Lin28 polypeptide, wherein the origin of said induced pluripotent stem cell is a non-human species.

18. The induced pluripotent stem cell of claim 17, wherein said non-human species is selected from the group consisting of mouse, rat, hamster, guinea pig, rabbit, cat, dog, pig, sheep, goat, cow, horse, and monkey species.

19. The induced pluripotent stem cell of claim 17, wherein said induced pluripotent stem cell was induced from a somatic cell.

20. The induced pluripotent stem cell of claim 19, wherein said somatic cell is selected from the group consisting of skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells.

21. The induced pluripotent stem cell of claim 17, wherein said human Sox family polypeptide is a Sox2 polypeptide.

22. The induced pluripotent stem cell of claim 17, wherein said human Klf family polypeptide is a Klf4 polypeptide.

23. The induced pluripotent stem cell of claim 17, wherein said human Myc family polypeptide is a c-Myc polypeptide.

24. The induced pluripotent stem cell of claim 17, wherein said induced pluripotent stem cell comprising nucleic acid encoding said human Oct3/4 polypeptide, a human Sox2 polypeptide, a human Klf4 polypeptide, and a human c-Myc polypeptide.
25. An induced pluripotent stem cell, wherein said induced pluripotent stem cell was obtained using nucleic acid encoding one or more polypeptides selected from the group consisting of a non-human Oct3/4 polypeptide, a non-human Sox family polypeptide, a non-human Klf family polypeptide, a non-human Myc family polypeptide, a non-human Nanog polypeptide, and a non-human Lin28 polypeptide, wherein the origin of said induced pluripotent stem cell is human.

26. The induced pluripotent stem cell of claim 25, wherein said one or more polypeptides are of mouse, rat, hamster, guinea pig, rabbit, cat, dog, pig, sheep, goat, cow, horse or monkey origin.

27. The induced pluripotent stem cell of claim 25, wherein said induced pluripotent stem cell was induced from a human somatic cell.

28. The induced pluripotent stem cell of claim 27, wherein said human somatic cell is selected from the group consisting skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells.

29. The induced pluripotent stem cell of claim 25, wherein said non-human Sox family polypeptide is a Sox2 polypeptide.

30. The induced pluripotent stem cell of claim 25, wherein said non-human Klf family polypeptide is a Klf4 polypeptide.

31. The induced pluripotent stem cell of claim 25, wherein said non-human Myc family polypeptide is a c-Myc polypeptide.

32. The induced pluripotent stem cell of claim 25, wherein said induced pluripotent stem cell comprising nucleic acid encoding said non-human Oct3/4 polypeptide, a non-human Sox2 polypeptide, a non-human Klf4 polypeptide, and a non-human c-Myc polypeptide.
33. An induced pluripotent stem cell, wherein said induced pluripotent stem cell was obtained using a non-integrating vector comprising nucleic acid encoding one or more polypeptides selected from the group consisting of a Oct3/4 polypeptide, a Sox family polypeptide, a KIf family polypeptide, a Myc family polypeptide, a Nanog polypeptide, and a Lin28 polypeptide, wherein said induced pluripotent stem cell lacks said nucleic acid.

34. The induced pluripotent stem cell of claim 33, wherein said vector is a viral vector.

35. The induced pluripotent stem cell of claim 33, wherein said vector is a non-viral vector.

36. A method for obtaining a population of induced pluripotent stem cells, wherein said method comprises:
   (a) providing cells with nucleic acid encoding Oct3/4, Sox2, Klf4, and c-Myc polypeptides, and
   (b) culturing said cells with medium lacking serum under conditions to obtain said population of induced pluripotent stem cells.

37. The method of claim 36, wherein said medium lacks feeder cells.

38. The method of claim 36, wherein said medium lacks non-human feeder cells.

39. A method for repairing diseased heart tissue in a mammal, wherein said method comprises administering induced pluripotent stem cells to said mammal under conditions wherein said diseased heart tissue is repaired, wherein said induced pluripotent stem cells were obtained using one or more polypeptides or nucleic acid encoding said one or more polypeptides selected from the group consisting of a Oct3/4 polypeptide, a Sox family polypeptide, a KIf family polypeptide, a Myc family polypeptide, a Nanog polypeptide, and a Lin28 polypeptide.

40. The method of claim 39, wherein said administering step comprises an intramyocardial administration.
41. The method of claim 39, wherein progeny of said induced pluripotent stem cells become engrafted into heart tissue of said mammal.

42. The method of claim 39, wherein progeny of said induced pluripotent stem cells become engrafted into heart tissue of said mammal without disrupting cytoarchitecture.

43. The method of claim 39, wherein said method restores contractile performance, ventricular wall thickness, or electrical stability.

44. The method of claim 39, wherein said method restores contractile performance, ventricular wall thickness, and electrical stability.

45. The method of claim 39, wherein said administering step results in the regeneration of cardiac, smooth muscle, or endothelial tissue.

46. The method of claim 39, wherein said administering step results in the regeneration of cardiac, smooth muscle, and endothelial tissue.

47. The method of claim 39, wherein said induced pluripotent stem cells were induced from somatic cells.

48. The method of claim 47, wherein said somatic cells are selected from the group consisting of skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells.

49. The method of claim 39, wherein said Sox family polypeptide is a human or non-human Sox2 polypeptide.

50. The method of claim 39, wherein said KIf family polypeptide is a human or non-human KIf4 polypeptide.
51. The method of claim 39, wherein said Myc family polypeptide is a human or non-human c-Myc polypeptide.

52. The method of claim 39, wherein said induced pluripotent stem cells comprise nucleic acid encoding a human Oct3/4 polypeptide, a human Sox2 polypeptide, a human Klf4 polypeptide, and a human c-Myc polypeptide.


54. The method of claim 39, wherein said Nanog polypeptide is a human Nanog polypeptide.

55. The method of claim 39, wherein said Lin28 polypeptide is a human Lin28 polypeptide.

56. The method of claim 39, wherein said induced pluripotent stem cells were induced from human somatic cells.

57. A method for regenerating cardiovascular tissue in a mammal, wherein said method comprises administering induced pluripotent stem cells to said mammal under conditions wherein progeny of said induced pluripotent stem cells become engrafted with cardiovascular tissue of said mammal, wherein said induced pluripotent stem cells were obtained using one or more polypeptides or nucleic acid encoding said one or more polypeptides selected from the group consisting of a Oct3/4 polypeptide, a Sox family polypeptide, a Klf family polypeptide, a Myc family polypeptide, a Nanog polypeptide, and a Lin28 polypeptide.

58. The method of claim 57, wherein said administering step comprises an intramyocardial administration.

59. The method of claim 57, wherein said progeny become engrafted into heart tissue of said mammal.
60. The method of claim 57, wherein said progeny become engrafted into heart tissue of said mammal without disrupting cytoarchitecture.

61. The method of claim 57, wherein said method restores contractile performance, ventricular wall thickness, or electrical stability.

62. The method of claim 57, wherein said method restores contractile performance, ventricular wall thickness, and electrical stability.

63. The method of claim 57, wherein said administering step results in the regeneration of cardiac, smooth muscle, or endothelial tissue.

64. The method of claim 57, wherein said administering step results in the regeneration of cardiac, smooth muscle, and endothelial tissue.

65. The method of claim 57, wherein said induced pluripotent stem cells were induced from somatic cells.

66. The method of claim 65, wherein said somatic cells are selected from the group consisting of skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells.

67. The method of claim 57, wherein said Sox family polypeptide is a human or non-human Sox2 polypeptide.

68. The method of claim 57, wherein said Klf family polypeptide is a human or non-human Klf4 polypeptide.

69. The method of claim 57, wherein said Myc family polypeptide is a human or non-human c-Myc polypeptide.
70. The method of claim 57, wherein said induced pluripotent stem cells comprise nucleic acid encoding a human Oct3/4 polypeptide, a human Sox2 polypeptide, a human Klf4 polypeptide, and a human c-Myc polypeptide.

71. The method of claim 57, wherein said Oct3/4 polypeptide is a human Oct3/4 polypeptide.

72. The method of claim 57, wherein said Nanog polypeptide is a human Nanog polypeptide.

73. The method of claim 57, wherein said Lin28 polypeptide is a human Lin28 polypeptide.

74. The method of claim 57, wherein said induced pluripotent stem cells were induced from human somatic cells.

75. A population of cardiomyoctes derived from induced pluripotent stem cells, wherein said induced pluripotent stem cells were obtained using a human Oct3/4 polypeptide, a human Sox family polypeptide, and a human Klf family polypeptide or nucleic acid encoding said human Oct3/4 polypeptide, said human Sox family polypeptide, and said human Klf family polypeptide, wherein the origin of said induced pluripotent stem cell is human, and wherein said induced pluripotent stem cells were not contacted with an exogenous human cMyc polypeptide.

76. The population of cardiomyoctes of claim 75, wherein said induced pluripotent stem cell was induced from a human somatic cell.

77. The population of cardiomyoctes of claim 76, wherein said human somatic cell is selected from the group consisting skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells.

78. The induced pluripotent stem cell of claim 75, wherein said human Sox family polypeptide is a Sox2 polypeptide.
79. The population of cardiomyocytes of claim 75, wherein said human Klf family polypeptide is a Klf4 polypeptide.

80. The population of cardiomyocytes of claim 75, wherein said induced pluripotent stem cell comprising nucleic acid encoding said human Oct3/4 polypeptide, a human Sox2 polypeptide, and a human Klf4 polypeptide.
<table>
<thead>
<tr>
<th></th>
<th>HCF</th>
<th>BJ</th>
<th>MRC-5</th>
</tr>
</thead>
<tbody>
<tr>
<td>No vector infection</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ocl/Sox/Klf/Myc</td>
<td>16</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ocl/Sox/Klf</td>
<td>0</td>
<td>N.D.</td>
<td>16</td>
</tr>
<tr>
<td>Ocl/Sox/Klf/Lin28/Nanog</td>
<td>0</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
<tr>
<td>Ocl/Sox/Klf/Lin28/Nanog</td>
<td>2*</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
</tbody>
</table>

*After expansion, all the clones showed non-ES-like morphology.

FIG. 3

SUBSTITUTE SHEET (RULE 26)
FIG. 7

MEF

Ki67
DAPI

iPS

Ki67
DAPI

SSEA1
DAPI

SSEA1
DAPI
FIG. 11
Post-ischemic intra-myocardial

2 wks

FIG. 19E

Subcutaneous

4 wks

FIG. 19D

Immunocompetent

SUBSTITUTE SHEET (RULE 26)
FIG. 20D

FIG. 20E

SUBSTITUTE SHEET (RULE 26)
FIG. 21A

28/55

LVD, mm

+ fib  + iPS

Pre upper 95%
lower 95%

FIG. 21B

+ fibroblasts

LVDd

LVDs

2 mm

200 ms

+ iPS

PWTd

PWTs

SUBSTITUTE SHEET (RULE 26)
FIG. 22C

FIG. 22D

FIG. 22E

SUBSTITUTE SHEET (RULE 26)
Native

Transduced

FIG. 25C

FIG. 25D

FIG. 25E

FIG. 25F

FIG. 25G

FIG. 25H

STRICT TO SHEET (RULE 26)
in vitro embryoid body differentiation

Day 0

hanging drop

Day 5

FIG. 26A

SUBSTITUTE SHEET (RULE 26)
**Fig. 33A**

Bar chart showing the percentage of 3F-iPS contracting EB over time (d7 to d11) for Clone 1 and Clone 2.

**Fig. 33B**

Image showing a scale of 200μm and a graph of beating (AU) over time (0 to 10 seconds).

*SUBSTITUTE SHEET (RULE 26)*
Adulthood

FIG. 35J

FIG. 35I

FIG. 35J

FIG. 35K

SUBSTITUTE SHEET (RULE 26)